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Abstract 
 
In this study the enhancement of the proteasome inhibitor activity by colloidal 
gold nanoparticle delivery was evaluated in pancreatic and prostate cell lines. 
Chitosan-gum Arabic-gold nanoparticle structures are also proposed as another 
approach for specific drug delivery to cancer cells. 
Proteasome inhibition is a current therapeutic strategy used in the treatment of 
multiple myeloma. Drugs controlling proteasome activity are ideally suited for 
unidirectional manipulation of cellular pathways such as apoptosis. The first 
proteasome inhibitor approved in clinics was bortezomib. This drug is currently used 
in combination with other anticancer agents.  
The cellular uptake of the two nanosystems - gold nanoparticles coated with 
poly(ethylene glycol) and chitosan-gum Arabic matrix- gold nanoparticle - was studied 
in pancreatic (S2-013 and hTERT-HPNE) and prostate (Du145) cell lines by laser 
scanning confocal microscopy. Adenocarcinoma and normal cells internalized 
pegylated gold nanoparticles, which show no toxicity up to concentrations of 1.0 nM. 
The formation of endocytic vesicles with high electron density particles was observed 
and might explained the activity of the proteasome inhibitor at very low 
concentrations in the presence of the gold nanoparticles.  The internalization of 
bortezomib promoted by the particles leads to its rapid accumulation and diffusion in 
the cytoplasm yielding to an increased toxicity to the cancer cells when compared to 
the drug alone. Concerning Du145 cells, it was observed a significant cell viability 
reduction with bortezomib concentrations as low as 4 nM in the presence of gold 
nanoparticles. The proteasome inhibitor alone had to be present at concentrations of 
at least 120 nM to induce identical cytotoxicity response. 
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Cytotoxic assays established that the positively charged nanosystem - chitosan-
gum Arabic-gold nanoparticles - reduces the cell growth and cell proliferation of S2-
013s but this effect was not observed in hTERT-HPNE cells.  
The capacity of chitosan-gum Arabic nanocarriers to deliver gold 
nanoparticles/anticancer drug is showed and a decrease of the drug concentration 
needed to cause toxicity in HPNE cells was demonstrated. 
These findings demonstrate that gold nanoparticles can be used as effective 
delivery system, enhancing the permeation and retention of the drug in pancreatic 
and prostate cells and open the possibility to decrease multi-drug resistance. In vitro 
results of functionalized gold nanoparticles, internalized by cancer cells, pave the way 
for a more efficient proteasome inhibitor delivery and release in adenocarcinoma 
cells.  
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Resumo 
 
O presente estudo visa estudar a atividade de um inibidor de proteassomas 
transportados em nanopartículas de ouro em linhas celulares neoplásicas do 
adenocarcinoma pancreático e prostático. Outra abordagem neste estudo consiste no 
desenvolvimento de nanopartículas de quitosano-goma-arábica como sistemas de 
libertação de fármacos anticancerígenos. 
A inibição de proteassomas é uma estratégia terapêutica usada no tratamento 
de mieloma múltiplo. Na verdade, os fármacos controladores da atividade do 
proteassoma são fundamentais na manipulação e degradação de proteínas 
responsáveis pelo ciclo celular e iniciadores da apoptose. O bortezomib é o primeiro 
inibidor de proteassomas aprovado em tratamentos clínicos. Este medicamento é, 
atualmente, utilizado em combinação com outros agentes anticancerígenos. 
Os estudos de internalização celular dos dois nano-sistemas – as nanopartículas 
de ouro funcionalizadas com polietilenoglicol e as nanopartículas de ouro 
encapsuladas numa matriz de quitosano-goma-arábica foram estudados em linhas 
celulares pancreáticas (S2-013 e hTERT-HPNE) e prostáticas (Du145) por microscopia 
confocal. As nanopartículas de ouro internalizadas pelas células neoplásicas e não 
neoplásicas não mostram citotoxicidade para concentrações até 1.0 nM. A formação 
de vesículas endocíticas de nanopartículas com uma elevada densidade eletrónica são 
observados e poderá explicar a atividade inibidora do proteassoma, com 
concentrações bastante baixas de fármaco, na presença de nanopartículas de ouro. A 
internalização do bortezomib promovida pelas nanopartículas conduz à rápida 
acumulação e difusão no citoplasma, levando ao aumento de toxicidade nas células 
neoplásicas quando comparado com o fármaco. Nas células Du145 foi observada uma 
significativa redução na viabilidade celular com a concentração de bortezomib de 4 
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nM na presença de nanopartículas de ouro. Quando o inibidor é utilizado sozinho, a 
sua concentração será de 120 nM para induzir uma resposta idêntica à anteriormente 
nomeada. 
Os ensaios de citotoxicidade com os nano-sistemas permitiram verificar que há 
uma redução do crescimento e proliferação celulares das S2-013, mas a mesma 
resposta não foi observada nas hTERT-HPNE. 
A capacidade dos nano-transportadores de quitosano-goma-arábica para a 
entrega de nanopartículas de ouro/agentes anti-tumorais é apresentada e é 
demonstrada a minimização de toxicidade das drogas em células HPNE. 
Estes resultados demonstram que as nanopartículas de ouro podem ser 
utilizadas como sistemas de transporte de fármacos, que permitem aumentar o 
efeito de permeabilidade e retenção tanto nas células pancreáticas como nas células 
prostáticas. Este sistema poderá conduzir à diminuição de resistência a múltiplas 
drogas. Os resultados in vitro da internalização de nanopartículas de ouro 
funcionalizadas por células neoplásicas possibilitam a eficiência no transporte e 
libertação dos inibidores de proteassomas. 
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 1 Preface 
 
Nanoparticle formulation, functionalization and characterization are important 
advances in biomedicine that contribute to the development of new approaches for 
the treatment and diagnosis of diseases such as cancer. Recent studies show that 
nanoparticle size, degree of hydrophobicity, stability and reduced toxicity are 
important factors that determine the ability of the systems to cross cell barriers in 
order to reach specific areas of the body and to deliver biomolecules to tissues 1.  
Nanoparticles have shown to be promising delivery systems for cancer therapy 
applications and diagnostics. Different approaches are currently being investigated for 
the targeted delivery of anticancer drugs with minimal side effects 2, 3. Some 
nanosystems have been developed due to their specific properties, biocompatibility 
and biodegradability 4, 5. Some vehicles have been successfully applied in the clinic 4. 
Nonetheless it is fundamental a continuous investigation for developing safe 
nanomaterials as nanocarriers for therapeutic and diagnostics applications.  
This thesis focuses on the delivery of an anticancer drug, bortezomib, by 
inorganic based nanocarriers for cancer treatment. Bortezomib (BTZ) is a dipeptide 
boronic acid, FDA-approved inhibitor of 26S proteasome function, crucial to induce 
toxicity and apoptosis in tumour cells 6. Functionalized gold and gold-polysaccharide 
(chitosan-gum Arabic) nanoparticles were developed in order to (a) enhance the drug 
therapeutic efficacy in cells leading to effective combination therapies against cancer 
and low toxicity; (b) ability to deliver the anticancer drugs to specific sites and (c) 
understand the internalization mechanism of the particles by cancer cells. 
The present thesis is organized into six chapters. This chapter, Introduction, 
presents the purposes and scope of this research. Chapter 2, Background, introduces 
the state-of-art of drug delivery systems in biomedical applications, particularly in 
cancer therapies. In Chapter 3, Material and Methods, the preparation and 
Preface 
 
4 
characterization of the nanosystems are described. In Chapter 4, the BTZ loaded 
pegylated gold nanoparticle system is presented and its toxicity in prostate and 
pancreatic cells is evaluated. Chapter 5 presents the system of BTZ+pegylated gold 
nanoparticles loaded in chitosan-gum Arabic nanoparticles and the results concerning 
their toxicity in pancreatic cells. Chapter 6, Concluding Remarks, sums up the main 
outcomes of this thesis. 
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 2 Background 
 
Contents 
 
2.1 Introduction---------------------------------------------------------------------------7 
2.2 Design of nanoparticles for anticancer drugs delivery-----------------------8 
2.3 Metal based nanoparticles --------------------------------------------------------15 
2.4 Polymeric nanoparticles-----------------------------------------------------------17 
 
 
2.1 Introduction 
Drug delivery systems (DDS) have been of a considerable focus of attention as 
promising tools to attain better retention and release of therapeutic and diagnostic 
agents and thus to overcome the limitations of conventional therapies. The increase 
of the treatment efficacy by targeting the anticancer drugs selectively to cancer cells 
is a challenge of nanotechnology-based DDS 7. Nanosystems are currently being 
developed to transport and distribute the drugs, in a direct and controlled way, as 
well as to activate them in situ 8. This leads to a decrease of the relative anticancer 
drug concentration and side effects in normal host tissues 2, 3, 5, 7, 9-12.  
Nanosystems like dendrimers, liposomes, metal based nanoparticles, micelles, 
vesicles, nanoemulsions, quantum dots and polymer nanoparticles have been 
developed to solve limitations of the myriad existing drugs, such as poor solubility at 
physiological pH, biodistribution and cell uptake 2, 7, 10, 13-19. Biocompatibility, 
biodegradability and stability are also crucial factors that should be taken into 
consideration 4, 5, 10, 15, 16. Physical-chemical properties such as chemical composition, 
shape, roughness, hydrophobicity or hydrophilicity, hydrodynamic diameter and 
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surface charge influence the biocompatibility and stability of the nanosystems 1, 4. 
Table 2.1 highlights some types of materials used in nanocarrier preparation for 
application as drug delivery systems 3, 5, 20, 21. 
 
 
 
An overview of polymeric and metal-based nanoparticles, in particular, 
polysaccharides nanoparticles and AuNPs, for cancer therapy is presented. 
2.2 Design of nanoparticles for anticancer drug 
delivery  
Nanoparticles (NPs) have potential in therapeutics and diagnostics applications. 
They can improve several limitations of the chemotherapy agents 14. Chemotherapy 
agents used in cancer treatment are capable of blocking critical cell cycle phases 
leading to apoptosis of tumour cells 10. However chemotherapy success rate has 
limitations and depends on each patient. The anticancer activity is not selective in 
tumour tissues, often causing damage to healthy tissues 8, 10, 21, 22. The unfavorable 
pharmacokinetics,  and administration at high doses of the agents with poor solubility 
leads to a low circulation time in the body associated to the limitations of 
conventional chemotherapy 2, 4, 8, 14, 23. The effectiveness of the anticancer drug 
Table 2.1 Nanosystems in drug delivery applications.  
Dendrimers Poly(amidoamine). 
Fullerenes Carbon based nanocarriers. 
Inorganic nanoparticles Gold nanoparticles (AuNPs); carbon nanotubes; 
mesoporous silica nanoparticles. 
Polymer-based 
nanoparticles 
Polylactic acid; Poly(cyano)acrylates. 
Polyethyleinemine; Polysaccharides including 
alginate, chitosan, gum Arabic; 
 Phospholipids; 
Liposomes Phospholipids. 
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targeting to a specific site by nanoparticles will have an enormous impact in cancer 
treatments 15.  
NPs offer advantages such as the improvement of bioavailability, controlled 
time release, modifications on pharmacologic and pharmacodynamics properties of 
the active drugs and a significant reduction of unwanted systemic side effects 21, 22, 24. 
The advantages and disadvantages of nanoparticles are summarized in Table 2.2.   
 
Table 2.2 Nanoparticles advantages and disadvantages.  
Nanoparticles advantages 
Easy modification to achieve transport drug targeting 
Biocompatibility  
Low toxicity  
Drug protection and controlled release 
Good stability  
Increase solubility of the anticancer drug preserving its activity 
Targeting delivery at site 
Reduction of side effects 
Nanoparticles disadvantages 
Possibility of toxicity of the materials 
Need for surgical intervention either for the systems’ applications or 
removal 
Particle aggregation, making physical handling of nanoparticles difficult 
in liquid and dry forms 
High cost of drug production 
 
NPs can increase the anticancer drug concentration in tumour cells by passively 
or actively targeting the tumour tissue 20, 25.  
Through active targeting, specific marker agents for cancer cells are used, 
modifying the drug nanosystem. A targeted moiety having selective affinity for 
interacting with a specific tissue or cell is conjugated to the nanocarrier. The 
molecules that acts as penetration enhancers are capable to recognize and bind to 
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other biomolecules 7, 10. The targets could be receptors, enzymes, peptides and 
antibodies 25. 
Nanosystems can be accumulate, gradually, at the target site, in solid tumours 
via the enhancing the permeation and retention (EPR) effect (Figure 2.1), decreasing 
the toxicity while therapeutic effects are maintained 5, 7, 8, 20, 21, 25, 26.   
 
 
 
Solid tumours have particular pathophysiological characteristics such as 
abnormal angiogenesis 27. Angiogenesis is the process that involves the growth of new 
blood and lymphatic vessels which is stimulated when tumour tissues require 
nutrients and oxygen 28, 29. Consequently, angiogenesis is the crucial process that 
generates the development and growth of disease, particularly the growth of tumours 
29. Figure 2.2 shows the tumour angiogenesis process. This occurs due to disorders in 
the balance between stimulating and inhibiting elements 29. Therefore, solid tumours 
reveal hyper vascular permeability, defective vascular architecture and poor 
lymphatic drainage compared with normal tissues 3, 21, 22, 27, 30, 31. These features of 
 
Figure 2.1 Passive targeting delivery –  the EPR effect.  
 
 
Background 
 
 
11 
solid tumours are described as EPR effect. Leaky blood vessels are present with 
irregular shape and the endothelial cells are disorganized 22, 32. Nanocarriers have the 
capacity to deliver high anticancer drug doses, increasing their half-life time and 
reducing their side effects by selective targeting tumour tissues and vasculature 8, 10, 21, 
30, 31, 33. Several studies reported nanocarriers that contribute to  the EPR effect 22, 27.   
 
 
 
It is reported by several studies that nanoparticles are internalized into cancer 
cells through endocytosis (Figure 2.1) 34, 35. The nanosystem is confined in endocytic 
vesicles. Usually, incubation with nanoparticles in cell media leads to adsorption of 
serum proteins on nanoparticles’ surface that facilitates their uptake mechanism by 
cells 36. Kim et al. studied the influence of nanoparticle internalization on the cell cycle 
phase 37. The uptake of nanoparticles by cells was studied and characterized by 
transmission electron microscopy (TEM) methods in order to understand the 
mechanisms of potential nanoparticle toxicity 34, 38-40.  
Continuous research has been focused on nanosystems’ behaviour within 
biological systems. When the nanocarriers are administered to the body, there is an 
immune response in order to protect it against the foreign NPs. It has been studied 
 
 Figure 2.2 Angiogenesis process.  
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that small NPs (10 to 100 nm) can avoid being detected and cleared by a component 
of the immune system, the reticuloendothelial system (RES), by the opsonisation 
process 41. The intravenous administration of NPs leads to the recognition of the 
nanosystems by the immune system that are then cleared by phagocytes. Hence, it is 
important to decrease the adsorbed blood components - the opsonins – from the 
nanoparticle’ surface, making them less visible to phagocytic cells 25. This can be 
achieved by the development of NPs functionalized with hydrophilic 
polymers/surfactants such as poly(ethylene glycol) layer, poloaximine and 
polysorbate 80 4, 8, 20. The addition of modifiers to nanocarriers is possible through 
their surface functionalization leading to increased stability. Also, due to effective 
repulsive forces between nanocarriers, aggregation and precipitation are avoided, 
prolonging their in vivo circulation time 4, 5, 8.   Efficient loading of chemotherapeutic 
agents, such as doxorubicin, paclitaxel, carboplatin, into NPs has been reported 42-46. 
Table 2.3 presents some colloidal carriers that are under development or on the 
market. These systems showed either equal or higher anticancer drug efficacy 
compared to regular chemotherapy. The anticancer drug agents can be loaded into 
the NPs by encapsulation, entrapment or surface attachment 14.  Also, NPs are able to 
overcome the resistance to several anticancer drugs developed by most of tumour 
cells and, consequently, target the drug to cells 8, 14.  Nanoparticles may be 
administered by different routes, which include intravenous, intramuscular, and 
subcutaneous injection, as well as peroral, ophthalmic and transdermal 
administration 47.  
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Table 2.3 Colloidal systems under developmen t, clinical tr ials, or o n the 
market.  
Formulation Drug Product Application Status 
Pegylated  
liposome 
Doxorubicin 
Doxil Ovarian and 
metastatic breast 
cancer, multiple 
myeloma, kaposi’s 
sarcoma 48-52 
On the market  
 
NPs Livatag Hepatocellular 
carcinoma, liver 
cancer 53 
On the market 
liposomes Thermodox Breast, liver cancer 
54, 55  
 
Clinical trial 
Phase II and III  
On market 
Polymeric micelles 
(PEG-poly(aspartic 
acid) block 
copolymer) 
NK911 Solid tumours 56, 57 Clinical trial 
Phase I 
Polyisohexyl- 
-cyanoacrylate  
NPs 
 Hepatocellular 
carcinoma 42 
Under 
development 
Albumin NPs 
Paclitaxel 
Abraxane Lung, advanced 
ovarian, breast, 
metastatic 
pancreatic cancer 58-
61 
 
On the market 
Polymeric micelles Genexol-PM Lung and breast 
cancer  62-64 
On the market  
Clinical trial 
Phase II  
Cetyl 
alcohol/polysorbate 
NPs 
 Brain tumours: U-
118, HCT-15 cells 65 
Under 
development 
PEGAuNPs    Human 
tumour 
necrosis 
factor alpha, 
TNF 
Aurimmune  
(CYT-6091) 
Pancreatic, ovarian 
and breast cancer, 
melanoma, soft 
tissue sarcoma 66-68 
Clinical trial 
Phase II 
Liposome Uridine  Metastatic solid 
tumour 69 
Clinical trial 
Phase I 
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Formulation Drug Product Application Status 
Polymeric 
micelles 
Cisplatin NC-6004 Advanced solid 
tumour 70, 71 
Clinical trial 
Phase I/II/III 
Polymeric NPs Docetaxel Docetaxel-
PNP 
Advanced solid 
malignancies 72 
Clinical trial 
Phase I 
Liposome Daunorubicin Daunoxome Kaposi sarcoma 73 On the 
market 
 
The multidrug resistance (MDR) of the tumour cells conferred by the over 
expression of the plasma membrane p-glycoprotein might be reduced by NPs 15, 74. P-
glycoprotein recognizes the anticancer agent decreasing the influx agent and 
increasing the drug efflux out of the solid tumours, changing the apoptotic 
mechanism 8. Generally, MDR is a decrease of the drug accumulation in the specific 
site of tumour because of the overexpression of ATP-dependent pumps for xenobiotic 
compounds 8, 74. Several nanosystems have been evaluated to augment the drug 
control release and increase the tumour targeting, avoiding this problem of 
chemotherapy 74. The nanoparticles loaded with anticancer drug will cross the cell 
membrane without triggering the p-glycoprotein pump augmenting the capacity of 
anticancer drug distribution into tissue and cells 8, 15. Koziara et al. proposed a system 
able to overcome drug resistance in a human colon adenocarcinoma cell line (HCT-15) 
by paclitaxel entrapped in emulsifying wax NPs 75. A cytotoxicity study of doxorubicin 
(DOX) loaded pegylated gold NPs (PEGAuNPs) in hepatocellular cell line HepG2R 
showed ability to overcome MDR compared to free anticancer drug 76. The 
cytotoxicity study demonstrated that the Au-PEG-SS-DOX nanoconjugate system 
efficiently released the anticancer drug DOX and enhanced its cytotoxicity against 
MDR cancer cells. This study highlights the potential of using AuNPs for overcoming of 
MDR in cancer chemotherapy. Brown et al. revealed a significant growth inhibition of 
lung epithelial cancer cell line, A549, treated with oxaliplatin adsorbed onto 
PEGAuNPs 77. 
The NPs may increase the activation of the anticancer drug in the site of action 
and drug targeting in combination with other cancer therapies like radiotherapy 
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treatment. Radiation induced deoxyribonucleic acid (DNA) damage to cancer cells 
leading to a reduction in size or destruction of the tumour 10, 78, 79. Therefore, NPs act 
as radiopharmaceuticals or radiosensitizers in cancer treatment 10, 80. Metallic NPs can 
enhance, effectively, the radiation therapy by scattering and/or absorbing high-
energy electromagnetic waves (X-rays and gamma rays) 19. This fact contributes to the 
damage of DNA and cancer cells organelles. NPs can have influence in total radiation 
dose, minimizing it, and thus decreasing the radiation side effects 81. Several studies 
have been showing an increase in absorption of X-rays radiation when AuNPs are 
internalized in cancer cells 80, 82, 83. Hainfield et al. reported AuNPs as radiosensitizers 
84. They increase the local dose concentration of drugs and enhance the effects of X-
rays radiation. Results showed that the tumours were reduced by about 90% in size 
when treated with AuNPs and X-rays radiation, compared to radiation alone. The area 
of combination therapies in drug nanotechnology research is a highly emerging one. 
2.3 Metal based Nanoparticles 
Metal NPs have been studied for drug delivery applications. Inert metals such 
as gold and titanium are the most used for control release of anticancer drugs 85.  
AuNPs have been the focus of increasing number of studies due to their 
inherent and unique optical and chemical properties 86. AuNPs can be synthesized 
with different shape (spheres, rods, tubes, wires, ribbons, cubic, hexagonal, 
triangular) and size 86-89. They present a characteristic surface plasmon resonance 
band, absorb light in the near infrared region rendering them active for biological 
purposes 14, 90  91.  The expectable and easy surface modification chemistry through 
thiol linkages due to their reactive surface area, provides them the ability to carry 
high drug doses 20, 91-93. 
AuNPs can be synthesized via different methods. The biphasic Brust-Schiffrin 
method uses tetraoctylammonium bromide as the phase transfer reagent and sodium 
borohydride as reducing agent and allows the preparation of AuNPs with an 
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hydrodynamic diameter between 1 and 5 nm 94. Turkevitch et al. synthesized AuNPs 
with diameter range from 10 to 100 nm by the reduction of HAuCl4 with sodium 
citrate 95, 96. 
Characteristics such as charge, functionalized surface and size of AuNPs are 
important since they affect their cellular uptake 97-99. The mechanism of AuNP cellular 
uptake is controversial. Even though there are several studies reporting the fast 
uptake of positively-charged NPs by tumour cells, the presence of positive charges at 
the particle surface also leads to immune reactions 21. Neutral and negative NPs are 
considered better systems for clinical applications 21, 100. The most efficient cell 
internalization of NPs was observed for particles with size ranging between 20 and 50 
nm. Chan et al. showed that AuNPs with a diameter between 14 and 74 nm are able 
to be internalized by a HeLa cell model 101.  
AuNPs are used for many biomedical applications including as a drug delivery 
vectors based on covalent reaction, drug encapsulation, electrostatic adsorption and 
non-covalent conjugation 12, 20, 24, 41, 102-104. They can increase the anticancer effect of 
drugs by delivering them to cancer cells 105. This fact is facilitated by passive or active 
targeting mechanisms 106. Several studies showed that AuNPs interact with serum 
protein. Chithrani et al. studied the behavior of AuNPs when incubated with cell 
culture media. It was suggested that serum proteins are adsorbed at the particle 
surface, which mediate the AuNPs internalization via endocytosis process 101. 
Also, AuNPs might be a potential vector to avoid the RES clearance and 
enhance endothelial 3, 12. Mirkin et al. suggested that paclitaxel loaded 
oligonucleotide-AuNPs might overcome the drug-efflux in MDR cancers 107. Another 
example is the doxorubicin conjugated AuNPs for the treatment of breast cancer 108. 
The results showed an increase of cancer cell death compared to the free doxorubicin 
and an outgrown drug efflux from breast cancer cells. Patra et al. reported 
gemcitabine (anticancer drug) and cetuximab (anti-epidermal growth factor receptor) 
conjugated to AuNPs as an efficient nanosystem inhibitor of pancreatic tumour 
proliferation in vitro and in vivo 90. 
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Drug delivery by AuNPs delivery can be combined with non-invasive 
therapeutic effects such as radiofrequency ablation (RFA), photothermal therapy 
(PTT), photodynamic therapy (PDT) and radiotherapy 78, 105, 109, 110. Different studies 
reported better anticancer effects when NPs were combined with anticancer drugs 
and nonionizing radiofrequency (RF) radiation. Glazer et al. showed in vivo an increase 
on the pancreatic cancer cell apoptosis with combined therapies – cetuximab - and 
PAM4-conjugated AuNPs and RF radiation 111. El-Sayed et al. reported that the use of 
epidermal growth factor receptor (EGFR) coated AuNPs increased the photothermal 
therapy effect by 20 times of human oral squamous cell carcinoma, HSC3 112. 
PEGAuNPs are studied in several tumours and are systems that combined with 
chemotherapeutic agents offer a therapeutic strategy for advanced stage cancer 
patients 24, 113. The first clinical trial with PEGAuNPs was performed with aurimune 
(CYT-6091) in advanced cancer patients could result in a significant decrease of 
cytotoxicity of anticancer drugs 113. 
2.4 Polymeric Nanoparticles 
Polymeric NPs using biocompatible, stable and biodegradable polymers have 
been formulated to encapsulate hydrophilic and hydrophobic anticancer drugs and 
proteins 10, 21, 26, 114, 115.  Polymeric NPs confer advantages for the deliver of drugs 21, 26, 
116. These advantages are: 
 An increase of the drugs solubility and a better biodistribution; 
 Increase in stability of biomolecules and increase of their half-life time 14, 117, 
118; 
 Accumulation of the anticancer drug polymeric NPs at the tumour tissue due 
to the EPR effect 119, 120; 
 Targeting the drug to specific locations 121. 
Polysaccharides are polymers derived from algae, plants, microbial population 
and animals 122. Chitosan, alginate, heparin, hyaluronic acid and dextran are examples 
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of polysaccharides 123. They are high molecular weight compounds, classified 
according to their surface charges in cationic polysaccharides – chitosan - anionic 
polysaccharides – gum Arabic, alginate, heparin, hyaluronic acid and nonionic 
polysaccharides – dextran 7, 26, 124. Polysaccharide-based NPs can be prepared by 
different mechanisms: covalent crosslinking, ionic crosslinking, polyelectrolyte 
complexation and self-assembly of hydrophobically modified polysaccharides 123 
(Table 2.4) 123, 125, 126. 
 
Table 2.4 Methods used for the preparation of polysaccharide-based 
nanoparticles.  
Method Characteristics 
Covalent crosslinking Chemical interaction.  
Ionic crosslinking Polyanions/polycations with low molecular 
weight can act as ionic crosslinkers for charged 
polysaccharides. The most common crosslinker 
used is tripolyphosphate (TPP). 
Polyelectrolyte 
complexation 
Polymers with opposite charge surface can form 
polysaccharide NPs by electrostatic interaction. 
Self-assembly of 
Hydrophobically modified 
polysaccharides 
Spontaneous formation of micelles by polymeric 
amphiphiles through intermolecular connection 
between hydrophobic moieties.  
 
Chitosan (Ch) is a natural heteropolymer of N-acetyl-D-glucosamine and D- 
glucosamine liked by beta-(1-4)glycosidic bonds and it is obtained by deacetylation of 
chitin 26, 127. It presents low toxicity and it is hydrophilic, biodegradable and soluble in 
acidic solutions due to protonation of the amine groups 7. Ch play an important role in 
cancer therapy and can be explored for tumour angiogenesis inhibition 128. Ch has 
many advantages, including:  
 the ability to control the release of active agents;  
 avoiding the use of hazardous organic solvents while preparing particles;  
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 allowing for ionic crosslinking (cationic nature) with multivalent anions: it has 
mucoadhesive character, which increases the residual time at the site of 
absorption 129. 
Gum arabic (GA) (Acacia) is a negatively charged branched polysaccharide. Its 
biocompatibility and biodegradability confer to this polyelectrolyte numerous 
advantages 130. The composition analysis of GA reveals the presence of a main 
galactan chain carrying heavily branched galactose/arabinose side chains. The 
carbohydrate moiety is composed of D-galactose (40% of the residues), L-arabinose 
(24%), L-rhamnose (13%), and two types of uronic acids, responsible for the 
polyanionic character of the gum, D-glucuronic acid (21%) and 4-O-methyl-D-
glucuronic acid (2%) 131. Liu et al. suggested that AuNPs form a novel nanocomposite 
in the presence of GA 132. The system can be promising as photothermal agents for 
cancer treatment 132. Effiong et al. revealed that GA-modified magnetic NPs inhibit 
the proliferation of E. coli in media 133. Avadi et al. developed a nanoparticulate 
system based on ionic gelation between Ch and GA for oral delivery of insulin 134.  
NPs can entrap the anticancer drugs into their matrix or absorb them onto their 
surface 123 127. The loading efficacy depends on the NPs preparation and 
physicochemical properties of the anticancer drug/biomolecule. Anticancer drugs 
such as doxorubicin, paclitaxel, 5-fluoroaucil have been encapsulated using polymeric 
NPs. Fonseca et al. reported an increase of the inhibitory growth effect with paclitaxel 
loaded to  poly(lactic-co-glycolic) acid (PLGA) NPs in human small cell lung cancer cell 
line, NCl-H69 when compared to free anticancer drug 135. Another study showed 
similar results, supporting the use of these NPs as a promising drug delivery 
nanosystem. In fact, in HeLa cells, a higher inhibitory growth effect is revealed with 
paclitaxel-loaded PLGA NPs when compared to the drug alone 136. 
Nah et al. prepared the paclitaxel loaded in water-soluble Ch NPs. The NPs 
were produced by conjugation of hydrophilic group, methoxy poly-(ethylene) glycol p-
nitrophenyl carbonate and an hydrophobic group, cholesteryl chloroformate  to the 
free amine groups of chitosan 137. The results suggested a high nanoparticle 
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accumulation in a tumour induced murine model and, therefore, a considerable 
anticancer effect. Sahu et al. showed a good cytotoxicity of paclitaxel loaded folic acid 
(FA) modified chitosan NPs in tumour cells 138.  
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3.1 Materials 
Bortezomib (Velcade) was purchased from Selleck Chemicals LLC (USA). 
Chitosan 250 kDa (degree of deacetylation > 93%) was purchased from Altakitin 
(Portugal). High molecular weight chitosan (Ch, 310–375 kDa based on the viscosity 
range of 800–2000 mPa.s, degree of deacetylation > 75%), gum Arabic (GA, Mw ~ 
250,000, viscosity 60 mPa s), glacial acetic acid, sodium hydroxide and sodium 
chloride, trisodium citrate dehydrate and tetrachloroauric (III) acid (HAuCl4; 99.99% 
trace metals basis, 30 wt% in dilute HCl), acetic acid, Potassium bromide (KBr), 
dimethyl sulfoxide (DMSO), sulforhodamine B (SRB) and trypan blue were purchased 
from Sigma-Aldrich (Germany). Phosphate buffered saline (PBS: 0.01 M, 0.0027 M KCl, 
0.137 M NaCl, pH 7.4) were purchased from Fluka (Germany). α-thiol-ω-carboxyl 
(polyethylene glycol) (molecular weight 394.57 Da) was purchased from Prochimia 
(Poland). Tricloroacetic acid (TCA) and Tris buffer were acquired from Merck 
(Darmstadt, Germany). Roswell Park Memorial Institute-1640 medium-(RPMI-1640 
medium), fetal bovine serum (FBS), L-glutamine, penicillin and streptomycin were 
purchased from Invitrogen (Spain). Trypsin, Dulbecco’s modified Eagle’s medium 
(DMEM) and PrestoBlue®Cell Viability Reagent (PB) were obtained from Invitrogen 
Co. (Scotland, UK). 20S proteasome enzyme (human erythrocyte), substrate Suc-LLVY-
AMC (molecular weight 763.9 Da), proteasome assay buffer were purchased from 
Enzo Life Sciences (Switzerland).  
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3.2 Systems 
3.2.1 Synthesis of pegylated gold nanoparticles 
Gold nanoparticles (AuNPs) (pH of 5.1) were synthesized by reduction of HAuCl4 
using sodium citrate (Turkevich-Frens method) 96, 139. Briefly, HAuCl4 aqueous solution 
was heated to slight boiling and stirred. Trisodium citrate was added and boiled for 15 
min. Then, pegylated-modified gold nanoparticles (PEGAuNPs) were prepared by 
mixing AuNPs with α-thiol-ω-carboxyl (polyethylene glycol) (PEG) capped with a 
carboxylate group at a molar ratio of 1:1000. The mixture was stirred at room 
temperature for about 1 h. The resultant solution was centrifuged by three washing 
steps with water, at 13400 rpm (12000 g) during 10 min to remove the unbound PEG 
molecules. The pH of PEGAuNPs was 5.3. The concentration of the PEGAuNPs was 
determined by the Lambert-Beer Law assuming the molar absorptivity of the AuNPs 
plasmon resonance band at 526 nm being 2.33 x 108 M-1 cm-1 140. 
3.2.2 Mixture of bortezomib with functionalized gold 
nanoparticles 
A fresh BTZ solution was prepared in DMSO at room temperature (0.01 mg·mL-
1). The mixture of BTZ and the PEGAuNPs (BTZ+PEGAuNPs) was prepared by adding 
BTZ to PEGAuNPs solution to obtain the final BTZ concentrations presented in Table 
3.1. The samples were prepared in DMEM and RPMI-1640 medium (pH of 7.0-7.4) for 
pancreatic and prostate cell lines, respectively.  
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The main objective was to use the solutions in the range of the BTZ 
concentrations as previously defined above, with PEGAuNPs concentrations range of 
0.1, 0.5 and 1.0 nM. 
3.2.3 Preparation of chitosan-gum Arabic complexes 
Solutions of the complexes were prepared with two different initial 
concentrations of Ch, 0.04% 0.06% and 0.3% (w/v), and different GA concentrations 
according to the weight ratios. 
Ch solutions were prepared by dissolving the suitable mass in 1% aqueous 
acetic acid solution, followed by the pH adjustment to 4.8, with 10% aqueous sodium 
hydroxide solution. GA was dissolved in ultrapure water. The pH of the GA solutions 
ranged from 5.0 to 5.6. The complex preparation involved the mixture of aqueous 
 Table 3.1 BTZ concentrations used in prostate and pancreatic cancer 
cell assays. 
                Cell line type 
 
CBTZ (nM) 
Prostate Pancreatic 
0.001    
0.01    
0.1    
1.0    
4.0    
7.76    
10.0    
15.5    
46.4    
50.0    
77.6    
100.0    
124.2    
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phases of the two macromolecules, adding 5 mL of the correspondent GA solution to 
5 mL of a Ch solution dropwise and under gentle magnetic stirring for 30 min at room 
temperature. The final pH was 4.8 and the ionic strength was 0.04 M. The charge 
ratios were calculated assuming 23% of charge residues for GA (glucoronic acids). 
3.2.4 Preparation of PEGAuNPs loaded Ch-GA NPs 
PEGAuNPs loaded complexes of chitosan-gum Arabic were prepared in the 
same conditions of Ch-GA NPs. PEGAuNPs were added to the GA under magnetic 
stirring for 15 min at room temperature, followed by the addition of Ch solution 
dropwise for more 15 min. The initial concentration of Ch was 0.04% (w/v) and Ch/GA 
weight ratio of 1:1.2. The final PEGAuNPs concentration in Ch-GA-PEGAuNPs was 2 
nM. The pH of Ch-GA-PEGAuNP suspension was 4.7. 
3.2.5 Preparation of BTZ loaded Ch-GA NPs 
A fresh BTZ solution was prepared in DMSO at room temperature and was 
added to GA solution, under homogenization for 15 min at room temperature. After, 
Ch solution was added dropwise and homogenized for more 15 min. The initial 
concentration of Ch was 0.04% (w/v) and Ch/GA weight ratio was of 1:1.2. The final 
BTZ concentration was 200 nM. The BTZ loaded Ch-GA (Ch-GA-BTZ) NPs pH was 4.8. 
3.2.6 Preparation of Ch-GA NPs loaded with 
BTZ+PEGAuNPs 
The mixture of BTZ and the PEGAuNPs was prepared by adding BTZ to 
PEGAuNPs solution to obtain the final PEGAuNPs and BTZ concentrations of 2.0 and 
200.0 nM, respectively. Briefly, followed the preparation of the fresh BTZ+PEGAuNPs, 
GA solution was added, drop by drop at room temperature. After 15 min of 
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continuous magnetic stirring, Ch solution (0.4% w/v) was added. Stirring was 
continued for 15 min. The Ch-GA NPs loaded with BTZ+PEGAuNPs (Ch-GA-
BTZ+PEGAuNPs) pH was 4.6. 
3.3 Methods 
3.3.1 Dynamic Light Scattering 
Dynamic light scattering (DLS) is the most popular experimental method for the 
characterization of complex liquids like colloidal suspensions, polymer solutions and 
others 141. For this technique, it is necessary to know some parameters as the 
temperature and viscosity of the sample. The temperature value must be constant; if 
not, convection in the sample will implicate non-arbitrary movements and, 
consequently, incorrect interpretation of the particles size. One change on the surface 
of the particles will affect the diffusion speed and, thus, the size of the particles. 
DLS determines the size of particles and their size distribution in dispersion. The 
incident light source from the laser illuminates the sample contained in a cell. This 
intensity of the scattered light depends on the Brownian motion of the particles, an 
arbitrary movement of the particles as a consequence of the contact with the solvent 
molecules and their thermal energy causing a Doppler Shift. The intensity of the 
scattered light that fluctuates with time is detected using a suitable optical 
arrangement and is correlated with the particle size. 
The hydrodynamic diameter of the particles measured is that of a sphere 
having the equal translational diffusion coefficient as the particle being measured. In 
this case, it is assumed that the particles are spherical and the hydrodynamic radius 
value is calculated based on translational diffusion coefficient by using the Stokes-
Einstein relation 142: 
H
S
R
kT
D
6
                       (3.1) 
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where HR  is Laser hydrodynamic radius of the scattering particle; SD is the 
translational diffusion coefficient, which depends on the size of the particle, on the 
surface structure and on the concentration and type of ions in solution; k  is the 
Boltzmann’s constant; T is the absolute temperature value and   is the viscosity. 
The hydrodynamic diameter of the nanoparticle’ suspension was analysed by 
dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments Ltd., 
Malvern, UK), keeping the samples at 25ºC. Size measurements were performed at a 
scattering angle of 173º in a 12 mm square polystyrene cuvette (Sarstedt, Germany).   
3.3.2 Zeta Potential 
Zeta potential ( , ZP) corresponds to a physical property and gives an 
indication of the stability of the system. The zeta potential of particles is determined 
by applying an Electrophoresis and measuring the velocity of the particles by Doppler 
Velocimetry (LDV). 
Electrophoresis is an electrokinetic effect and is based on the movement of the 
particles under an applied electric field to an electrode with opposite charge. Viscous 
forces on the particles tend to oppose this movement. When equilibrium is reached 
between these two opposing forces, the particles move with a constant velocity. The 
velocity depends on the viscosity ( ), the zeta potential, the dielectric constant ( ) 
and it is denominated electrophoretic mobility ( E ). 
Henry’s equation143 relates electrophoretic mobility to zeta potential: 



3
2 )(kaf
E

                      (3.2) 
where  is Henrys function and can be 1.5 or 1.0. It is 1.5 when it is a 
Smoluchowski approximation for an aqueous solution. For small particles with low 
dielectric constant and in non-aqueous solutions, the Henrys function is 1.0 and it is 
the called Huckel approximation. 
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A particle is considered stable if it has an absolute value of zeta potential of 30 
mV or more. The particles will repel each other and there isn’t tendency for 
flocculation 141. 
The zeta potential of nanoparticle suspensions and complexes was determined 
by laser Doppler velocimetry, respectively, using a Zetasizer Nano ZS (Malvern 
Instrument s Ltd., Malvern, UK), at 25ºC. The zeta potential was obtained by using a 
disposable capillary cell (DTS 1060, Malvern). 
3.3.3 Transmission Electron Microscopy 
Transmission electron microscopy (TEM) is useful to interpreting the particle 
size, structure and geometry of samples 144. In TEM a beam of electrons is transmitted 
through the sample, interacting with the specimen as it passes through 145. The final 
image is two-dimensional. Negative staining is used to provide sufficient contrast to 
allow visualization of biological samples such as polymers and DNA. Uranyl acetate 
crystals is one of the most used negative staining dye. The presence of salt residues of 
buffers can decrease the contrast of the sample. 
TEM images were acquired using a Jeol JEM-1400, JEOL operated at 60 kV. 5 µL 
of each sample was placed on carbon formvar-coated grid and let to adsorb for 2 min. 
The staining was performed with 1% (w/v) of filtered aqueous solution of uranyl 
acetate for 45 seconds. After, the grid was washed twice with deionized (DI) water to 
remove the excess.  
3.3.4 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) uses electrons that interact with atoms of 
the surface sample producing radiation signals and allows to obtain images of high 
resolution. It is possible to have information about the topography and the 
composition of the sample.  
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An electron beam is generated by an electron gun and is focussed by a series of 
electromagnetic lenses. The scan coils are adjusted to focus the incident electron 
beam onto the sample; these adjustments cause fluctuations in the voltage, 
increasing/decreasing the speed in which the electrons come into contact with the 
surface of the sample. The electrons are released from the surface of the sample, 
creating a magnetic field that deflects the beam and radiation signals are produced. 
The signal is collected by detectors, converted into a voltage and amplified. The image 
corresponds to several points of intensity. 
Scanning electron microscopy measurements were performed using a SEM 
(JEOL JSM-6301F, JEOL Ltd., Tokyo, Japan), to study the morphological properties and 
to confirm the size of PEGAuNPs. 
3.3.5 Laser Scanning Confocal Microscopy 
Laser scanning confocal microscopy (LSCM) detects structures obtaining by light 
from a single focal plane of the sample without light out of focus. The light out of 
focus, which is not originated from the microscope focal plane, is eliminated via a 
pinhole that is placed in front of the detector. The light that hits the sample, it excites 
fluorescence and this radiation is collected by the objective, it passes to the detector. 
The image corresponds to the intensity of the pixel that is directly proportional to the 
intensity of the fluorescence light detected. 
Imaging experiments were performed with the prostate (Du145) and pancreatic 
(S2-013 and hTERT-HPNE) cell lines. The cells were grown for 24 h, in a 12-well µ-
Chamber (ibidi, Germany) (800cells/well) under normal conditions (5% CO2 humidified 
atmosphere at 37ºC). Then the cells were incubated with 0.5 nM of PEGAuNPs, 1 nM 
of BTZ alone and 1 nM BTZ + 5 nM PEGAuNPs for a period of incubation of 30 min and 
48 h. In case of polysaccharides nanosystems the cellular uptake of Ch-GA-
BTZ+PEGAuNPs with BTZ concentration of 100 nM was studied using pancreatic cells 
(S2-013) and immortalized human pancreatic duct epithelial cells (hTERT-HPNE) for 
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the same period of incubation. Following the incubation, the cells were rinsed with 
1% of phosphate buffered saline (PBS) and fixated using 4% paraformaldehyde for 15 
min. The cells were washed with PBS and mounted in a glycerol-based non-drying and 
non-hardening medium. Imaging was performed using a laser scanning confocal 
microscope TCS SP5 II (Leica Microsystems, Germany). To evaluate the nanoparticle 
internalization by cells, the control untreated cells were also imaged. Different areas 
were analysed and at least three images were acquired for each type of cell. Cell 
imaging showed reproducible results. 
3.3.6 Atomic Force Microscopy 
Atomic force microscopy (AFM) is a scanning probe microscopy technique used 
to study the topology of surfaces using force measurement and manipulate properties 
of chemical and biological surfaces, with little sample preparation, in three 
dimensions at the nanoscale 146. AFM has better resolution than optical microscopes 
and it guarantees the best topographic contrast, not only by direct measurements of 
the surface but also by quantitative height information 147.  
The basic physical principle of this scanning probe method is the interaction 
between a scanning probe and the sample. This interaction ranges between different 
kinds of forces and reflects the tip geometry and material 148. Then, it contributes, by 
different way, to the measured force between the tip and sample on the basis of the 
cantilever deflection. The deflection of the cantilever is measured by a laser, which 
reflected off the back of the cantilever onto a photodetector. The piezoelectric tube 
moves the sample in the z direction for maintaining a constant force, and in x and y 
directions for scanning the sample. Hooke’s law gives the tip-sample force by: 
cxkF                       (3.3) 
where F  is the force of interaction between the tip and the surface of the 
sample, cx  is the deflection of the cantilever and k  is the spring contact of the 
cantilever 149. 
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AFM can operate by two modes. In contact mode, the equipment operates by 
scanning a static tip across the sample. In this case, the AFM tip is brought close to 
the sample surface and the scanner makes the final adjustment on the tip. The piezo 
movements Z are recorded as a function of x  and y  position. The height image is 
the final image and shows the sample surface topography. 
In tapping mode AFM, also known as intermittent contact, the cantilever 
oscillates up and down, at a constant drive frequency and drive amplitude; while the 
tip scans the sample surface by intermittent contact, the amplitude drops. Thus, the 
tip lightly taps the surface of the sample, while rastering and only touches the sample 
at the bottom of each oscillation.  
AFM imaging was performed in tapping mode (at about 14 kHz, near the 
resonant frequency of the cantilever) and in liquid (water), using a Veeco Multimode 
Nanoscope 4A. The cantilevers had a nominal radius of curvature of 20 nm. The 
samples were diluted (1:60) and a drop (50 µL) was deposited onto freshly mica 
surface and let to adsorb for at least 30 min, at room temperature. AFM imaging was 
acquired with unmodified silicon nitride tips (DNP, Veeco Instruments, USA). At least 
three regions of the surface of the complexes were examined to verify if morphology, 
shape and structure were similar in the sample. The images were analysed using the 
JPK Image Processing software.  
3.3.7 Absorption Spectroscopy 
The concentration of gold nanoparticles was estimated from UV absorbance 
( A ) at around 526 nm according to the Beer-Lambert law: 
LC
I
I
A ..)(log  010                      (3.4) 
where 0I  is the intensity of the incident light at a given wavelength, I  is the 
transmitted intensity, L  is the distance through the sample and C  is the 
concentration of the absorbing specie;   is a constant known as the molar 
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absorptivity or extinction coefficient, which is a molecular property in a given solvent 
at a specific temperature and pressure. 
UV-Vis absorption spectra of the samples PEGAuNPs and BTZ+PEGAuNPs were 
carried out using a 1 cm quartz cuvette, at room temperature by Shimadzu UV-1700 
PharmaSpec spectrophotometer. 
3.3.8 Fluorescence 
The fluorescence intensity corresponds to a process of the emission of light by 
a molecule which is in an excited state (higher energy state) because it absorbed light 
energy before 150.  The intensity of fluorescence is dependent on the absorbance, 
according to Beer-Lambert law eq. 3.4. 
When the molecule absorbs the energy light exh , it changes to a higher 
quantum state of energy – excited state (S1), and it can fluoresce. After that, the 
molecule stays instable and returns to the lowest energy state, the ground state (S0), 
by emitting a photon with a characteristic energy 150, 151. The time of excited state of 
the molecule is denominated excited lifetime. The difference of energy between both 
is denominated Stokes shift 150.  
The fluorescence spectrometer is composed by a light source, which emits a 
range of different wavelengths of light. For one wavelength value, the light passes 
through an excitation monochromator and then through the sample cell. Afterward, 
in absorption and re-emission of the energy, many wavelengths may appear due to 
electron transitions and Stokes shift. To separate and analyze them, the fluorescent 
radiation passes through an emission monochromator and it is registered by a 
detector 152. 
BTZ activity was studied with the 20S proteasome assay kit – BML-AK740 (Enzo 
Life Sciences). A fluorescence standard curve of BTZ was measured for concentrations 
between 10 nM and 300 nM.  
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Incubation assays with BTZ and BTZ plus PEGAuNPs were performed at 37ºC, 
during 50 min. BTZ activity alone and in the presence of PEGAuNPs was monitored as 
the reaction substrate’s fluorescence emission (excitation at 360 nm, emission at 485 
nm) using a microplate reader (PowerWave HT Microplate Spectrophotometer, 
BioTek). 
3.3.9 ATR-FTIR  
Fourier transform infrared spectroscopy (FTIR) is a technique used to identify 
chemical compounds and substituent groups by comparison with known spectra of 
compounds 153. A compound exposed to infrared light absorbs infrared energy at its 
characteristic frequencies. During the analysis, the sample’s transmittance and 
reflectance on the infrared region at various frequencies is converted and the result is 
a FTIR spectrum 154.  
The Infrared region of the electromagnetic spectrum is usually divided into 
three regions: far-IR (400-20 cm-1 wavenumber), which has adjacent rotational energy 
level changes; mid-IR (400-1400 cm-1), which has correlated to fundamental 
vibrational level changes, and near-IR (14000 – 4000 cm-1), which causes vibrational 
and rotational level changes 155. 
The transmittance (T ) is: 
 b
I
I
T
o
 exp                      (3.5) 
where I  is the intensity of the transmitted radiation by the sample, 0I  is 
intensity of the incident radiation 156.  
The equipment used has a beam source that contains different frequencies of 
light at once and it measures how much of that beam is absorbed by the sample. The 
light shines according to configuration of mirrors denominated Michelson 
interferometer, which allows some wavelengths to pass through and blocks others. 
The light from the polychromatic infrared source is accumulated and directed to a 
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beam splitter. The best way is the light reflected from the two mirrors back to the 
beam splitter and 50% of the original light passes into the sample. After that, the light 
is refocused to the detector. Then, the measured signal (information about the 
characteristics frequencies and intensities of the spectrum) is digitized and sent to the 
computer where the Fourier transformation takes place. The raw data is a set of 
intensities measured for discrete values of retardation, being interpreted and 
manipulated according to algorithm Fourier Transform 157. 
The BTZ+PEGAuNPs, PEGAuNPs and BTZ solutions were analysed by Attenuated 
total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR). The samples 
were dried in a drying oven (Scientific, model BTC-9090) for 24 h.  The dried samples 
were added to KBr and ATR-FTIR spectra were recorded with an ALPHA FTIR 
Spectrometer (Bruker) in the spectral range 4000-400 cm-1, resolution of 4 cm-1 and 
64 scans, at room temperature. 
3.3.10 Turbidity measurements 
Coacervation process between arabic gum and chitosan results in the formation 
of a complex that can be analysed by turbidimetric measurements 158. 
The turbidity of the samples was measured with a Shimadzu UV-1700 
spectrophotometer at a wavelength of 500 nm as a function of time at 25 ºC using 1 
cm path length cuvette. The turbidity (T ) was defined as: 






0I
IT ln                      (3.6) 
with I  the light intensity that passes through a volume of solution in 1 cm3 and 
0I  the incident light intensity. 
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3.3.11 In vitro release studies  
Drug release studies of the BTZ from the systems  BTZ+PEGAuNPs, Ch-GA-BTZ 
NPs and Ch-GA-BTZ+PEGAuNPs were carried out at 37ºC by dialysis using a 
regenerated cellulose membrane (molecular weight cut off, MWCO: 8–10 KD, 
purchased from Spectrum Labs Europe BV, Netherlands). The initial PEGAuNPs and 
BTZ concentration were 5 nM and 210 μM, respectively. In case of the Ch-GA-BTZ 
NPs, Ch-GA-BTZ+PEGAuNPs, the BTZ concentration used was 200 µM. The solutions 
were incubated in 6 ml of DI water and in PBS 0.01 M, with constant magnetic stirring. 
The BTZ concentration of the dialysate buffer was analysed with time using 
spectrophotometric analysis at 270 nm (Shimadzu UV-1700 PharmaSpec 
spectrophotometer). The concentration of BTZ that was released was calculated from 
the standard calibration curves of BTZ solution in DI water and in PBS 0.01 M. 
3.3.12 In vitro cell assays 
Du145 cell line, derived from solid tumour tissue (human prostate carcinoma) 
was grown using a standard RPMI, supplemented with 10% (v/v) fetal bovine serum, 
1% L-glutamine, and 1% penicillin and streptomycin. The cell cultures were 
maintained at 37ºC in 95% humidified atmosphere and 5% CO2.  
Human pancreatic cancer cell line (S2-013) and immortalized human pancreatic 
duct epithelial cells (hTERT-HPNEs) were provided by Professor M. A. Hollingsworth 
(UNNC - Omaha, USA). The cells were maintained in DMEM medium, supplemented 
with 10% FBS under 5% CO2 humidified atmosphere at 37 ºC. 
All the procedures must be made under sterile conditions to avoid 
contaminations. Viable cells were counted using an automated Coulter counter (Vi-
Cell XR, Beckman-Coulter Inc., Miami, FL, USA). 
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Radiotherapy principle of cancer 
The use of X-rays is an innovation in cancer therapy that allows 
destruction/killing of cancer cells. This treatment can be used alone or associated 
with other anticancer treatment protocols as chemotherapy, surgery 159. Radiation 
therapy works in a certain part of the body – local treatment. This can stop or control 
cancer cells from growing and spreading 160. The SI unit of absorbed dose is the gray 
(Gy) and it is the amount of radiation required to deposit one joule of energy in one 
kilogram of any kind of matter 161. 
When a high radiation kills cells by damaging DNA, their ability to grow is 
blocked. This is the basic principle of radiation therapy.  
 
In vitro cytotoxicity study 
The evaluation of the cytotoxicity of BTZ, PEGAuNPs, BTZ+PEGAuNPs was 
performed in prostate cancer cell line, Du145 by a colorimetric cell proliferation assay 
based on measuring the retention of methylene blue (MB) in ethanol-fixed cells; and 
in pancreatic cell lines, S2-013 and hTERT-HPNE by PrestoBlue (PB) and 
Sulforhodamine B (SRB) assays. Ch-GA-BTZ NPs and Ch-GA-BTZ+PEGAuNPs 
cytotoxicity study was evaluated against pancreatic cell lines by PB and SRB assays. 
 
MB assay 
The cell viability of Du145 cells incubated with the particles was determined by 
the colorimetric cell proliferation assay. 
Cells were seeded in 96 well plates at a density of 6000 cell/well for 24 h. 
Samples – BTZ alone, PEGAuNPs and BTZ+PEGAuNPs, at different concentrations were 
added to the cells and incubated, at 37 ºC during 24 h at the BTZ concentrations 
ranging between 4.0 and 124.2 nM. After this period, the solution of each well was 
removed and fresh medium was added and the incubation proceeded for 24 h more. 
For experiments using ionizing radiation the cells were irradiated with 160 kV X-
rays. The 96-well plates with the cultured cells were placed inside a CP160 X-ray 
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cabinet (Faxitron Bioptics, Tucson, AZ). Low energy radiation in 50–250 kV range has 
been shown to yield significant radiosensitization with AuNPs in brachytherapy 162-166. 
The dose rate was 1 Gy/min for 5 min and followed the incubation for 24 h more. 
Cell viability was determined by the cellular protein assay (MB assay) 167. The 
MB assay was found by Dent et al. to be a sensitive method for determining the 
response of cultured cells to growth factors with low variability 168. The cells were 
washed twice with phosphate saline buffer and fixed with 90% ethanol for 5 min. 
After that, 30 µL of filtered MB working solution (Sigma-Aldrich Co.) was added to 
each well and incubated for 15 min at room temperature. The plates were washed 
with cool tap water; then, 200 µL of 0.1% HCl was added and left for 30 min. 
Absorbance was measured at 675 nm using a microplate reader (PowerWave HT 
Microplate Spectrophotometer, BioTek). 
 
PB and SRB assays 
The effects of the nanoparticles and drug on the cell growth in the tested 
pancreatic cell lines were evaluated by two different assays based on PB 
(fluorescence) and SRB (colorimetric). Both assays allow an indirect estimation of cell 
number: the PB assay by the metabolization of resazurin to resofurin, and the SRB 
assay by staining cellular proteins with the dye SRB 169, 170. 
The S2-013 and hTERT-HPNE cells were seeded in 96-well plates (1000 cells per 
well) under normal conditions (5% CO2 humidified atmosphere at 37ºC) and allowed 
to adhere for 24 h. The cells were then treated for 48 h with: 
 BTZ, PEGAuNPs and BTZ+PEGAuNPs at the concentrations ranging 
between 0.001 and 100 nM BTZ; 
 Ch-GA-BTZ NPs and Ch-GA-BTZ+PEGAuNPs at the concentrations 
ranging between 0.01 and 100 nM BTZ; 
 Ch-GA NPs and Ch-GA-PEGAuNPs at the concentrations ranging 
between 1.1x10-7 to 3.3x10-3 mg/mL. 
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Following this incubation period 50 µL of PB reagent (diluted 1:10 in the DMEM 
medium) were added to each well and incubated for 45 min at 37ºC. The PB reagent 
is modified by the reducing environment of the viable cells turning into red colour and 
becoming fluorescent. The fluorescence was measured using a microplate reader 
(PowerWave HT Microplate Spectrophotometer, BioTek) at an excitation and 
emission wavelengths of 560 and 590 nm, respectively. 
For the SRB assay, the cells were fixated with 10% TCA for 1 h on ice. After the 
incubation period the cell monolayers were washed and stained with 50 μL SRB dye 
for 30 min. The cells were then washed repeatedly with 1% acetic acid to remove 
unbound dye. The cells were dried and the protein-bound stain was solubilized with 
10 mM Tris solution. 
The SRB absorbance at 560 nm was measured using the PowerWave microplate 
reader 170. Concentration for 50% growth inhibition (GI50) was evaluated from the SRB 
assay. The absorbance of the wells containing the nanoparticles or drug and the 
absorbance of the wells containing untreated cells following a 48 h incubation period 
were subsequently compared with that of the wells containing the cells that have 
been fixated at time zero (when the nanoparticles and drug were added) 171 . 
 
Statistical analysis for in vitro assays 
For each assay, three independent experiments were measured in triplicate. 
Statistical significance (p < 0.05) was determined by the Student’s t-Test. 
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4.1 Introduction 
This study was conducted to evaluate the efficacy to delivery bortezomib by 
gold nanoparticles into pancreatic and prostate cancer cells. 
Bortezomib (BTZ), also known as Velcade or PS-341, is a boronic dipeptide, 
which inhibits the function of the 26S proteasome, and is nowadays being studied for 
a wide diversity of cancer types 172, 173. Proteasome inhibitors and their associated 
mechanism of action in protein degradation and recirculation foresee large-scale 
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effects in the organism. Thus, drugs controlling proteasome activity are ideally suited 
for unidirectional manipulation of cellular pathways such as apoptosis. 
BTZ chemical structure is illustrated in Figure 4.1. 
 
 
 
BTZ blocks the activation of the transcription nuclear factor κB (NF-κB); induces 
apoptosis in prostate cancer cells - LNCaP, LAPC4, PC-3 and Du145 173-176. 
Limitations associated to anticancer drugs such as low bioavailability, little 
stability, poor specificity and development of resistance may be overcome by the use 
of nanoparticles (NPs), which offer the advantage of maximizing the retention of the 
drug in cancer cells and of minimizing its uptake in normal surrounding tissues 10, 78, 
177. Radiotherapy, which also causes toxicity by affecting healthy tissues, can benefit 
from this approach by selective absorption of radiation by NPs 10, 19, 78.  
Nanoparticle based systems show the capacity to cross biological barriers and 
be internalized in different cell cycle phases37. Gold nanoparticles (AuNPs) have been 
studied as vectors for cancer therapy and diagnostics 14, 24, 37, 87 109 178, 179. Several 
studies demonstrated that small sized AuNPs appear to be biocompatible, have low 
toxicity to human cells and show physical and chemical stability 14, 109, 180, 181. They are 
able to improve the delivery and efficacy of anticancer drugs 20, 106, 182. The AuNPs high 
reactive surface areas allow surface functionalization and immobilization of 
biomolecules 106, 109. Their strong affinity for hydrophilic molecules like polyethylene 
 
 
Figure 4.1 Chemical structure of BTZ.  
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glycol (PEG) modified with thiol groups has been reported 106, 183, 184. Pegylation of 
AuNPs (PEGAuNPs) increase their stability, and inhibits protein adsorption to their 
surface, which consequently prevents particle agglomeration 36, 185, 186. This fact is 
explained by the steric repulsion effect induced by the attached PEG molecules. There 
is also evidence showing that the conformation of PEG chains around the 
nanoparticles is responsible for an efficient cell uptake and for prolonging the 
circulation lifetime in the blood, since PEG confers flexibility to the AuNPs 36, 187. The 
bioconjugation with different molecules allows the formation of stable colloidal 
suspensions for targeted drug delivery applications 90  188  106. These properties make 
functionalized AuNPs a promising system to deliver anticancer drugs in chemotherapy 
and to overcome the problem of multi-drug resistance (MDR) 14, 90. 
Several in vitro studies have revealed that AuNPs can be used as delivery 
vehicles of anticancer drugs against pancreatic cancer cells, demonstrating inhibition 
of tumour cell proliferation 24, 90, 189. The nanoparticle cell internalization mechanisms, 
which might contribute to increase the drug effect, are still not understood.   
Recently, AuNPs have been proposed as potential candidates to assist 
radiotherapy by enhancing its efficiency 19, 78. Because it is expected that the 
nanoparticles will absorb high-energy photons, they would act as radiation sensitizers 
(radiosensitizers) minimizing the total radiation dose necessary to eradicate the 
tumour 10, 19, 78.  
The aim of this work is to provide insights into the mechanisms of activity 
enhancement of bortezomib (BTZ) by PEGAuNPs. The effect of PEGAuNPs combined 
with BTZ or ionizing radiation was studied on prostate cancer cells.  Also, the potential 
application of PEGAuNPs as a delivery vehicle of BTZ was studied using 
human pancreatic cancer cell line S2-013 and immortalized human pancreatic duct 
epithelial cells (hTERT-HPNE). Laser scanning confocal microscopy (LSCM) imaging was 
performed to follow the nanoparticle uptake by pancreatic and prostate cells. 
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Our study demonstrates the synergistic effect between PEGAuNPs and BTZ and 
can be extended to other cancer cell lines and drugs as a preliminary approach for 
new therapies.  
4.2 Results 
4.2.1 Physical characterization 
4.2.1.1 Particle size distribution, surface charge and 
morphology of BTZ loaded PEGAuNPs 
The size distribution and zeta potential of the BTZ loaded PEGAuNPs was 
determined by Dynamic light scattering (DLS) and Laser Doppler velocimetry (LDV), 
respectively. Negatively charged AuNPs were prepared through the reduction of gold 
salt by trisodium citrate, and were functionalized with α-thiol-ω-carboxyl 
(polyethylene glycol) (PEG).  
Their zeta potential was -47±4 mV and notably it changed to -13.6±0.5 mV after 
addition of 124.2 nM of BTZ, suggesting adsorption of the drug to the pegylated 
particles (Table 4.1). Schematic illustration of BTZ+PEGAuNPs is shown in Figure 4.2. 
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The pegylation of AuNPs does not significantly change the size of the 
nanoparticles. The average hydrodynamic diameter of PEGAuNPs was 20 nm and the 
polydispersity index (PdI) was 0.6 (Table 4.1 and Figure 4.3).  
 
Table 4.1 Hydrodynamic diameter, polydispersi ty index (PdI) and zeta 
potential of gold nanoparticles.  
 H2O 
                                       Parameters1 
Sample 
D (nm) PdI ZP (mV) 
AuNPs 14.4 nM (stock) 22 ± 0.4 0.6 -40 ± 1 
PEGAuNPs 12.2 nM (stock) 22 ± 0.3 0.6       -47 ± 4 
124.2 nM BTZ+ 12.2 nM PEGAuNPs 24 ± 0.3 0.6 -13.6 ± 0.5 
1D, diameter; ZP, zeta potential 
 
 
 
 
 
Figure 4.2 Schematic illustration of BTZ+PEGAuNPs.  
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TEM and SEM analysis (Figure 4.4) showed nanoparticles in suspension with 
spherical shape and size of 20 nm that is in agreement with DLS measurements. 
 
 
 
The particles show, in aqueous dispersion, a typical and distinctive surface 
plasmon resonance band centered at 526 nm (Figure 4.5). The concentration of 
PEGAuNPs was 12.2 nM, estimated by the Lambert-Beer Law. The addition of 
nanomolar concentrations of BTZ did not change the absorption λmax value of 
 
Figure 4.4 A) TEM image of PEGAuNPs; B) SEM micrographs of 
PEGAuNPs. The scale bar of TEM and SEM images is 100 nm.  
 
 
 
Figure 4.3 Characteristics of AuNPs: A) Size distribution chart of 
PEGAuNPs and BTZ+PEGAuNPs.  
 
B A 
BTZ loaded PEGAuNPs 
 
 
49 
PEGAuNPs and the BTZ absorption characteristic band was observed at 270 nm. The 
peak around 526 nm disappears for the nanoparticles suspended in RPMI medium 
due to the significant RPMI plasmon resonance band centered at 558 nm. From these 
results, we can conclude that the PEGAuNPs do not form aggregates in RPMI 
suspensions. 
 
 
4.2.1.2 Nanoparticle Stability 
The particle stability, with and without BTZ, in the presence of salt/serum 
medium (RPMI-1640 medium + FBS) was evaluated by hydrodynamic diameter and 
zeta potential measurements. In the presence of RPMI medium, significant changes in 
the zeta potential values were observed, which could be justified by the presence of 
the amino-acids and ions that are responsible for the screening of charges.  The 
addition of BTZ to the PEGAuNPs suspended in the RPMI-1640 medium does not show 
any effect in zeta potential value, contrarily to the results reported in DI water (Table 
4.1 and Table 4.2).  
 
 
Figure 4.5 Absorption spectra of BTZ+PEGAuNPs and PEGAuNPs.  
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Based on the results presented in Table 4.1 and Table 4.2, the mean size of the 
nanoparticle suspended in the RPMI-1640 medium increases 27% relatively to the 
PEGAuNPs suspended in DI water. This means that PEGAuNPs tend to form larger 
complexes in the RPMI-1640 medium due to most likely the fetal bovine serum 
protein adsorption into the nanoparticle surface contributing to steric forces between 
AuNPs. The spherical PEGAuNPs were stable and well dispersed for several months 
when stored at 4ºC in the dark (denoted by the absence of color change, aggregation, 
size and zeta potential). 
4.2.2 BTZ interactions with PEGAuNPs 
4.2.2.1 ATR-FTIR analysis 
Two different samples were analysed by ATR-FTIR spectroscopy: mixture of BTZ 
in powder plus dried PEGAuNPs (1) and the suspension of BTZ mixed with PEGAuNPs 
(BTZ+PEGAuNPs) that was dried (2). The spectra of the sample 2 showed a band at 
Table 4.2 Hydrodynamic diameter, polydispersity index (PdI) and zeta 
potential of gold nanoparticles suspe nded in DI water and 
RPMI/FBS medium. 
 H2O RPMI medium 
                       Parameters1 
Sample 
D (nm) PdI ZP (mV) D  (nm) PdI ZP (mV) 
PEGAuNPs 1.6 nM 22 ± 1 0.6 -47 ± 1 40 ± 1 0.5 -8 ± 0.5 
PEGAuNPs 0.1 nM 25 ± 1 0.4 -33 ± 2 41 ± 1  0.5 -8 ± 0.3 
4.0 nM BTZ + PEGAuNPs2 27 ± 2 0.6 -16 ± 5 35 ± 1 0.5 -8 ± 1 
40.0 nM BTZ + PEGAuNPs2 27 ± 0.3 0.6 -22 ± 1 34 ± 3 0.5 -8 ± 1 
400.0 nM BTZ + PEGAuNPs2 28 ± 0.4 0.2 -13 ± 2 36 ± 0.4 0.5 -7 ± 1 
1D, diameter; ZP, zeta potential 
2 PEGAuNPs concentration of 0.1nM  
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1528 cm-1 (N-H bend), which is not observed for the sample prepared by simply 
mixing the dried components (Figure 4.6). Since BTZ has a small extent of dissociation 
(pKa is 13.82), it acts as a base and there will be an electrostatic attraction between 
the negatively charged PEGAuNPs surface and BTZ, which is confirmed by the 
decrease of the zeta potential values.  
 
4.2.2.2 Assay of 20S Proteasome Activity 
The behaviour and interactions of BTZ with gold nanoparticles were studied by 
20S proteasome assay. In fact, to confirm the possibility of an enhancement of BTZ 
effect in the presence of PEGAuNPs, proteasome activity was measured in an aqueous 
model system.  
For BTZ concentrations up to 10 nM and constant PEGAuNPs concentration of 
0.1 nM, it is not possible to observe any activity because this concentration is below 
the detection limit of the method. According to the results presented in Figure 4.7, for 
BTZ concentrations of 20-50 nM, the fluorescence curves of BTZ alone and BTZ plus 
0.1 nM PEGAuNPs are similar without any significant changes in the BTZ activity. 
 
Figure 4.6 FTIR spectra of (1) mixture of BTZ in powder plus dried 
PEGAuNPs (2) BTZ+PEGAuNPs after drying. The spectra were 
shifted for a better visualization.  
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4.2.3 In vitro release studies 
The in vitro release experiment of BTZ+PEGAuNPs and BTZ alone were 
investigated using dialysis membranes (MWCO 8-10 kD) in DI water and in PBS 0.01 M 
at 37 ºC. The BTZ and PEGAUNPs concentrations were 210 µM and 5 nM, respectively. 
The results of BTZ dialysis are depicted in Figure 4.8. 
 
  
 
Figure 4.7 Kinetics of BTZ inactivation of 20S proteasome chymotrypsin -
like activity. Arbitrary fluorescence units (AFU) versus time. 
Control ( ), PEGAuNPs 0.1 nM ( ), BTZ 20 nM ( ), 
BTZ 20 nM plus PEGAuNPs 0.1 nM ( ), BTZ 50 nM ( ), 
BTZ 50 nM plus PEGAuNPs 0.1 nM ( ). 
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The release profiles showed that the BTZ release in PBS is much slower than in 
DI water (Figure 4.8). The BTZ release from the PEGAuNPs is pH dependent as it can 
be seen from the profiles in ultrapure water (pH 5.8) and in PBS 0.01 M (pH 7.0).  
 It was observed that in DI water, the BTZ release is slower with PEGAuNPs 
although after 4 h 55% of all the BTZ (Cmax) was released (Figure 4.8A). The behavior of 
BTZ released in PBS is very different as depicted by the concentration profiles of 
Figure 4.8B. In PBS, a delay in the BTZ release is observed in the first two hours, in 
comparison with BTZ alone, due to the presence of PEGAuNPs. The amount of BTZ 
released after 4 h was 56% and 15% for BTZ alone and in combination with 
PEGAuNPs, respectively. Also, after 30 h, 77% of the BTZ alone was detected in the 
outer solution of the dialysis membrane, whereas only 36% was released from the 
PEGAuNPs. The presence of PBS has an effect on BTZ release from the PEGAuNPs 
suggesting a stronger adsorption of the drug to the surface of PEGAuNPs. These 
results corroborate the zeta potential measurements, indicating that PBS has an 
effect on BTZ adsorption to the surface of PEGAuNPs, slowing down significantly the 
release process. These findings are particularly important to explain the 
BTZ+PEGAuNPs behaviour in cellular medium and the BTZ activity. 
 A  B 
 
Figure 4.8 BTZ release profiles ( ) and BTZ+PEGAuNPs ( ) versus time: A) 
in DI water; B) in PBS (0.01 M).  
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4.2.4 Cellular imaging studies 
The cellular uptake and intracellular distribution of the PEGAuNPs in prostate 
cancer cells (Du145), pancreatic cancer cells (S2-013) and immortalized human 
pancreatic duct epithelial cells (hTERT-HPNE) were assessed by Laser scanning 
confocal microscopy (LSCM) imaging technique (Figure 4.9 and Figure 4.10). An 
increase in the reflectance signal is observed in cells treated with PEGAuNPs 
compared to the untreated cells (control), which is attributed to the cellular uptake of 
PEGAuNPs 101. 
LSCM images of the Du145 cancer cells with the internalized PEGAuNPs are 
presented in Figure 4.9. 
 
 
On the contrary to other studies reporting the difficulty of cellular uptake of 
AuNPs after pegylation 182, 190, our observations show that PEGAuNPs are internalized 
by DU145, S2-013 and hTERT-HPNE cells. The PEGAuNPs are localized in the 
cytoplasm with higher concentration in the perinuclear region. The internalization of 
the nanoparticles by the pancreatic cells was detected after 30 min of incubation at 
 
Figure 4.9 Confocal reflectance images of Du145 cells at 48 h  of incubation. 
The cells were incubated with 0.5nM PEGAuNPs. Scale bar in all  
images is 10 μm.  
BTZ loaded PEGAuNPs 
 
 
55 
37ºC. Up to 48 h a well-defined accumulation of the PEGAuNPs is observed in 
endocytic vesicles at the perinuclear regions (Figure 4.10). 
 
 
 
Figure 4.11 corresponds to a 3D projection showing the PEGAuNPs distribution 
in the pancreatic cancer cell cytoplasm. 
 
 
Figure 4.10 Confocal reflectance images of the S2 -013 (a, c, e, g) and 
hTERT-HPNE (b, d, f, h) cells after 48  h incubation. (a and b) 
The cells were incubated with 1nM BTZ alone; (c and d) the 
cells were incubated with 0.5nM PEGAuNPs; (e and f)  the 
cells were incubated with 1nM BTZ+ 0.5 nM PEGAuNPs; (g 
and h) the control untreated cells. Scale bar in all images i s  
10 μM.  
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The PEGAuNPs form dynamic clusters where the nanoparticles move fast, 
which could be explained by Coulomb forces and osmotic repulsion as a consequence 
of their confinement in the endocytic vesicles (Figure 4.12). 
 
 
 
 
 
Figure 4.11 PEGAuNPs distribution in the cell cytoplasm.  
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4.2.5 Cytotoxic studies 
Following the observation of the PEGAuNPs cellular uptake, in vitro cytotoxicity 
studies were performed with BTZ and the PEGAuNPs. BTZ alone, PEGAuNPs and 
BTZ+PEGAuNPs were incubated with Du145, S2-013 and hTERT-HPNEs cells, at 37ºC, 
for 48 h and their effect was assessed by MB, PB and SRB methods.  
4.2.5.1 Prostate cancer cell line, Du 145 
As presented in Figure 4.13, PEGAuNPs up to 0.1 nM did not show any 
significant toxicity to the cells, which is corroborated by other findings 182, 191 
The effect of X-rays radiation (5 Gy) on prostate cell line in the presence of 
PEGAuNPs at different concentrations was analyzed (Figure 4.13). Irradiation with X-
rays leads to a 20% decrease in the cell viability, regardless of whether the cells are 
 
Figure 4.12 Schematic il lustration of the gold nanoparticle uptake into 
the pancreatic  cells: A) The PEGAuNPs and BTZ are 
internalized by endocytosis; B) The BTZ+PEGAuNPs confine 
in the vesicles and induce diffusion processes in the 
cytoplasm. Inside of the vesicles the nanoparticles move due 
to electrostatic repulsion and steric forces. Ac cumulation of 
the nanoparticles in the perinuclear region is observed due 
to disruption of some vesicles. Figure not to scale.  
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incubated or not with the colloidal solution (concentration range: 0.05–1.00 nM). 
Statistical analysis confirmed that the radiation and the non-radiation results are 
different (t test; p-value 0.0002) with means of 70% and 90%, respectively. 
 
The inhibitory effect of BTZ on the proliferation of Du145 cells was evaluated in 
the presence of PEGAuNPs at concentrations from 0.1 to 1.0 nM. All the results with 
BTZ combined with PEGAuNPs were obtained with a PEGAuNPs concentration of 0.1 
nM. This concentration was selected because it was the lowest PEGAuNPs 
concentration that enhanced the BTZ effect. Some experiments were performed with 
higher concentrations of PEGAuNPs but the results were similar and did not show 
significant improvements in the BTZ activity.  
A significant decrease in the cell viability occurred in the presence of 0.1 nM 
PEGAuNPs plus BTZ at concentrations from 4 to 124 nM (Figure 4.14).  
 
Figure 4.13 Viability of Du145 cells exposed to PEGAuNPs without BTZ 
and X-rays radiation (5 Gy).  
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The mixture significantly decreased the cell viability to 1% already for 4 nM BTZ, 
whereas the drug alone at this concentration had no effect (Figure 4.14). A 
concentration of BTZ alone of 124 nM reduced the cell viability to about 11%. Such 
synergistic behavior can be explained by the formation of AuNPs clusters inside the 
cells and in intracellular vesicles 36, 101, 182. The cells internalize AuNPs by the 
endocytosis process responsible for the high increase of BTZ concentration inside the 
Du145 cells when compared with the BTZ alone 182, 192, 193. 
4.2.5.2 Pancreatic cell lines, S2-013 and hTERT-HPNE 
Figure 4.15 showed that the PEGAuNPs at the concentrations up to 1.0 nM do 
not show any cytotoxicity on both pancreatic cell lines, sustaining by the cell integrity. 
 
 
Figure 4.14 Viability of Du145 cells exposed to BTZ and BTZ+PEGAu NPs. 
PEGAuNPs concentration  was 0.1 nM. 
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In the presence of BTZ combined with 1.0 nM of PEGAuNPs, the growth rate of 
the S2-013 cells decreased significantly when compared with BTZ alone (Figure 4.16).  
 
 
 A  B 
 
 C  D 
 
Figure 4.16 Effect of the BTZ+PEGAuNPs 1.0 nM (■) and BTZ alone (▼) on 
the cell growth of S2-013 (A, C) and hTERT-HPNE (B, D) cells. (A, 
B) SRB assay and (C, D) PB assay.  
 
 A  B 
 
Figure 4.15 Effect of PEGAuNPs on the cell growth of S2 -013 (A) and hTERT-
HPNE (B) cells.  
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Analysing the effect of BTZ at the concentrations in the range 0.1 - 1.0 nM, a 
significant difference in the cell growth is evident, 90-100% for BTZ alone and about 
50% for BTZ+PEGAuNPs (Figure 4.16A and Figure 4.16C). At this concentration range 
the drug toxicity on the hTERT-HPNE cells is not observed with the growth rate being 
97-100% (Figure 4.16B and Figure 4.16D). Our interpretation of these results is that 
apparently the S2-013 cell uptake kinetics is dependent on the PEGAuNP 
concentration in contrast to the hTERT-HPNE cell response, which is almost 
independent on the nanoparticle concentration (Figure 4.17).  
 
 
 
 A  B 
 
 C  D 
 
Figure 4.17 Effect of the BTZ+PEGAuNPs 1.0 nM (■), BTZ+PEGAuNPs 0.5 nM 
(●) and BTZ+PEGAuNPs 0.1 nM (▲) on the cell growth of the 
S2-013 (A, C) and hTERT-HPNE (B, D) cells. (A, B) SRB assay and 
(C, D) PB assay.  
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The analysis of the balance between cell proliferation and cell death showed an 
increase of the inhibitory growth effect with BTZ concentration (Table 4.3 and Figure 
4.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The GI50 concentration, obtained by the SRB assay, is significantly (p < 0.05) 
lower for the BTZ+PEGAuNPs 1.0 nM when compared to BTZ alone in the S2-013 cells 
(0.24 and 0.85 nM, respectively). Also, the efficacy of the BTZ+PEGAuNPs on inducing 
cell death is more pronounced than that of BTZ alone for drug concentrations above 
1.0 nM. For the hTERT-HPNE cells the GI50 concentration is significantly (p < 0.05) 
higher for the BTZ+PEGAuNPs 1.0 nM than that for BTZ alone (6.4 and 2.6 nM, 
respectively). 
 A  B 
 
Figure 4.18 Effect of the BTZ+PEGAuNPs 1.0 nM (■) and BTZ alone (▼) on 
the cell growth of the S2 -013 (A) and hTERT-HPNE (B) cells 
compared to the control, by the SRB assay.  
 
Table 4.3 Effect of BTZ and mixture of BTZ and PEGAuNPs on the growth 
inhibition of the pancreatic cell lines.  
 GI50 (nM) 
Sample S2-013 hTERT-HPNE 
BTZ 0.85 ± 0.17 2.57 ± 1.81 
BTZ+PEGAuNPs  1.0 nM 0.24 ± 0.03 6.42 ± 0.84 
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Moreover, the influence of the nanoparticle concentration on BTZ activity on 
S2-013 and hTERT-HPNE cells was analyzed. Our data show that BTZ+PEGAuNPs 1.0 
nM decrease significantly the S2-013 cell growth rate in comparison with 0.1 and 0.5 
nM PEGAuNPs (Figure 4.17A and Figure 4.17C). This effect is not observed in hTERT-
HPNE cells (Figure 4.17B and Figure 4.17D). Such difference can be explained by the 
different nanoparticle uptake kinetics by the two pancreatic cell lines. The potential 
enhancement of BTZ activity in the presence of PEGAuNPs was also evaluated by 
measuring the kinetics of the inactivation of chymotrypsin-like activity of the 20S 
proteasome by BTZ. In the absence of cell microenvironment, BTZ inhibitory activity in 
the presence of the PEGAuNPs (0.1 nM) remains constant (BTZ concentration range of 
20-50 nM). These results corroborate the cytotoxicity experiments and prove that the 
synergism between BTZ and PEGAuNPs on inhibiting the cell growth is only observed 
if cellular uptake of the nanoparticles occurs. 
4.3 Conclusions 
The present work demonstrates the ability of cells to internalize PEGAuNPs and 
the repercussion on the enhancement of permeation and retention of BTZ in prostate 
and pancreatic cancer cells, reducing the dose needed to decrease their viability.  
The significant increase of BTZ toxicity with PEGAuNPs at low concentration 
levels can be explained by the BTZ surface adsorption to the nanoparticles and 
cellular uptake mechanism observed by LSCM images.  In fact, the cell uptake 
mechanism induces a synergistic activity of the proteasome inhibitor and gold 
nanoparticles at very low drug concentrations.  This response may be due to a more 
efficient delivery of BTZ into the cells by PEGAuNPs maintaining the original activity of 
BTZ. These findings are also supported by the dialysis experiments in which a time lag 
and a significant decrease in BTZ release rate in PBS are observed when BTZ is 
combined with PEGAuNPs. 
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The pegylated gold nanoparticles internalized by prostate adenocarcinoma 
cells show no toxicity. Moreover the in vitro results with 0.1 nM PEGAuNPs and 4 nM 
BTZ show that it is possible to reduce the drug concentration 30 times to have the 
same effect as that of the drug alone.  
The effect of nanoparticle cell uptake and the formation of endocytic vesicles in 
the pancreatic cells increase the mass transfer rate across cell membranes and 
subsequently drug diffusion in the cytoplasm. The PEGAuNPs localized at the 
perinuclear region enhance the toxicity of BTZ at very low concentrations (0.1-1.0 nM) 
in the pancreatic cancer cells. At this level of concentrations, the passive transport of 
the drug alone through the cell membrane does not induce significant cytotoxicity.   
This process leads to high BTZ concentrations inside the cells compared to its 
low bulk concentrations, at which per se BTZ is not able to produce any cytotoxicity.  
The in vitro results reported pave the way for a better understanding of the 
AuNPs uptake mechanism by cancer cells and evidence the enhanced permeation and 
retention effect, opening the possibility to decrease MDR. Increasing the ability of 
drugs to penetrate tumour microenvironment in lethal concentration is particularly 
relevant in conventional chemotherapy of adenocarcinomas.   
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5.1 Introduction 
Polymeric nanoparticles are suitable drug nanocarriers due to their high 
capacity of encapsulation of molecules and endocytosis efficiency by enhanced 
permeation and retention (EPR) effect 194-196.  Also, it is reported that the circulation 
half-life time of drugs is improved and they are protected from inactivity during blood 
circulation and transport to the specific tissue 22, 120, 197-201. Moreover, the 
nanoparticles are biocompatible, stable 202. The control of the surfaces of the 
nanoparticles allows their interactions with negatively charged components from 
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plasma membrane. Nanoparticles are described to be internalized into cells by 
endocytosis 8, 100. These properties lead to improve drug delivery and reduction of the 
undesirable systemic side-effects in normal surrounding tissues 203, 204. Chitosan (Ch) is 
a cationic polysaccharide from the partial alkaline deacetylation of chitin 26, 199, 200.  It is 
a biodegradable and non-toxic polysaccharide that increases cell membrane 
permeability 120, 198, 205. Gum Arabic (GA), approved by the Food and Drug 
Administration, is an anionic polysaccharide prepared from the exudates of acacia 
trees 205, 206.  As a result, these polysaccharides have several suitable characteristics to 
improve drug nanocarriers and enhance drug therapeutic efficacy. 
Unique properties as biocompatibility, physical-chemical stability, namely high 
reactive surface, and non-toxicity make gold nanoparticles (AuNPs) eligible 
nanosystems for cancer treatment and diagnostics applications 14, 20, 87, 109, 181. Actually, 
AuNPs have been investigated for targeting drugs directly in situ, reducing several 
effects in the body, minimizing the multi-drug resistance (MDR) 14. Also, AuNPs were 
chosen to accumulate in tumours through the EPR effect 26.  
The presented investigation is focused on targeting a proteasome inhibitor, the 
bortezomib (BTZ), in combination with pegylated gold nanoparticles (PEGAuNPs), by 
incorporating them into chitosan-gum Arabic nanoparticles (Ch-GA-PEGAuNPs) to 
protect normal cells from the drug. PEGAuNPs combined with BTZ into Ch-GA NPs 
matrix were incorporated during the preparation of the polysaccharide matrix by 
complex coacervation. There are electrostatic interactions between the two 
polysaccharides with opposite charged surface, in solution. This process is often used 
to encapsulate biomolecules and to control their release 205, 207 
The anticancer activity of the BTZ is expected to be enhanced by its 
incorporation into the Ch-GA-PEGAuNPs but also to increase the systemic 
bioavailability of BTZ. The physicochemical properties and the in vitro cell uptake and 
cell growth of BTZ loaded Ch-GA-PEGAuNPs nanoparticles (Ch-GA-BTZ+PEGAuNPs) 
were studied in the human pancreatic cancer cells, S2-013 and the immortalized 
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human pancreatic duct epithelial cells, hTERT-HPNE, by laser scanning confocal 
microscopy. 
5.2 Results 
5.2.1 Physical characterization 
The complexes were prepared at pH 4.8 since at higher pH, chitosan has low 
solubility, whereas at pH below 4 the degree of ionization of GA is low. The chitosan 
molecules had two different degrees of deacetylation (DD), 75% (Ch75) and 93% 
(Ch93) and were prepared at two initial concentrations (CCh = 0.06 and 0.3%). The Ch 
concentrations after adding GA solution were 0.03% and 0.15%. The GA final 
concentrations depend on the ratios studied. GA/Ch weight ratios (RGA/Ch) were 0.6, 1, 
1.2 and 3, correlated to positive/negative charge ratios of 5.4, 3.3, 2.7, 1.1 for 
GA/Ch75 and 6.7, 4.0, 3.4, 1.4 for GA/Ch93. 
5.2.1.1 Assess complex formation 
GA/Ch75 mixtures at CCh = 0.03% and RGA/Ch 0.6, 1 and 1.2 were visually 
transparent, whereas all the other samples became turbid immediately after 
preparation (Figure 5.1A). The turbidity, monitored by spectrophotometry at 500 nm 
of the GA/Ch75 mixtures was close to zero at RGA/Ch up to 1.2 and increased to 0.50 at 
RGA/Ch of 3 (Figure 5.1B).  
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At higher concentrations (CCh = 0.15%), the samples showed turbidity ranging 
from 0.10 (RGA/Ch of 0.6) to 2.3 (RGA/Ch of 3) (Figure 5.1B). The complexes with CCh = 
0.15% and RGA/Ch of 3 precipitated after overnight incubation at room temperature. Ch 
DD93 at 0.03% and GA had turbidity close to zero for RGA/Ch of 0.6 which increased to 
0.10 and 1.0 for RGA/Ch of 1/1.2 and 3, respectively (Figure 5.1B). At Ch DD93 
concentration of 0.15% the turbidity increased from 0.70 to 2.7 (RGA/Ch 0.6 to 3) upon 
addition of GA. Precipitation of GA/Ch93 samples was observed at weight ratios of 3 
for CCh = 0.03% and at all ratios for CCh = 0.15%. 
The size of the complexes at CCh = 0.03% is similar and constant for both Ch 
DD75 and DD93 (240–260 nm) at RGA/Ch of 0.6 to 1.2, but increases to 360 nm at RGA/Ch 
of 3 (Figure 5.2).  
 
Ch 0.06% Ch 0.3% 
A 
 
B 
 
Figure 5.1 Macroscopic features (A) and turbidity (B) of GA/Ch complexes, 
immediately after preparation, at different ratios and two Ch 
concentrations: GA/Ch75 at 0.03% (■) and 0.15% (●); GA/Ch93 
at 0.03% (□) and 0.15% (○).  
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The hydrodynamic diameter of the complexes prepared with Ch DD75 at 0.15% 
decreased from 550 to 460 nm as the GA concentration increases from RGA/Ch 0.6 to 1, 
and is similar between ratios of 1 and 3 (Figure 5.2). The variation in the diameter of 
complexes containing Ch DD93 at 0.15% is less pronounced (540–600 nm). The 
polydispersity index (PdI) of the samples is greater than 0.1 and is higher for CCh = 
0.15%, indicating broad size distribution (Table 5.1). 
 
 
Figure 5.2 Mean hydrodynamic diameter of mixtur es of GA/Ch: Ch 
DD75% at 0.03% (■ )  and 0.15% (● ) or Ch DD93% at 0.03% (□) 
and 0.15% (○).  
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The complexes possess positive zeta potential indicating predominance of free 
amine groups at their surface (Table 5.1). At RGA/Ch of 3, the zeta potential values 
decrease and the complexes tend toward electroneutrality, which leads to their 
association and precipitation. 
If the turbidity of GA and Ch DD75 mixtures is low and no phase separation is 
observed, the detection of particles by DLS at RGA/Ch up to 1.2 and CCh = 0.03% can be 
explained by the formation of soluble complexes. At higher concentrations or using 
Ch DD93, the complexes become insoluble. The hydrodynamic diameter of the 
complexes containing Ch DD75 at 0.15% decreases upon increasing the concentration 
of GA, from RGA/Ch 0.6 to 1 due to the shrinkage of the complexes when more 
carboxylic groups interact with amine groups of Ch molecules resulting in a reduction 
of the intramolecular repulsion. However, this tendency, which is usually observed 
upon increasing the number of opposite charges, is not observed for the other cases. 
The number of positive charges is always higher than that of negative ones (Table 
5.1). Thus the core of the complexes must be composed of segments resulting from 
the local neutralization of positive charges of Ch. Given the fact that only 23% of GA 
residues are charged, its chains possess large non-charged segments, which might 
explain the lack of significant variation of their hydrodynamic diameters, despite the 
Table 5.1 Polydispersity index and zeta potential of GA/Ch complexes.  
 
complexes 
 
RGA/C h  
(+/) 
charge 
ratio 
PdI 
 
 
ZP 
0.03% 0.15% 0.03%  0.15%   
GA/Ch75 
0.6 5.4 0.38 ± 0.05 0.50 ± 0.05 37 ± 2 44 ± 5 
1 3.3 0.31 ± 0.04 0.41 ± 0.09 38 ± 4 44 ± 3 
1.2 2.7 0.29 ± 0.03 0.42 ± 0.11 35 ± 3 42 ± 2 
3 1.1 0.39 ± 0.08 0.50 ± 0.01 28 ± 2 26 ± 6 
GA/Ch93 
0.6 6.7 0.22 ± 0.04 0.27 ± 0.02 38 ± 2 51 ± 4 
1 4.0 0.18 ± 0.05 0.25 ± 0.01 39 ± 4 48 ± 3 
1.2 3.4 0.16 ± 0.04 0.38 ± 0.07 37 ± 2 47 ± 1 
3 1.4 0.24 ± 0.03 0.37 ± 0.04 31 ± 1 33 ± 2 
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increase in the number of negative charges in the medium. The increase in turbidity 
of mixtures containing 0.15% Ch indicates an increase in mass of the complexes. 
Increasing the GA/Ch ratio, macroscopic phase separation is observed. DLS 
measurements showed that there is a correlation between the average size and the 
polymer concentration. It was demonstrated that increasing the concentration of the 
polymer, its degree of ionization decreases, and it becomes more flexible as it is less 
expanded 158. Thus, the charged sites are more available for interaction, which 
associated to the fact that the number of macromolecules available in concentrated 
systems is higher lead to the formation of complexes with larger average size. At 
lower concentrations the charged polymers will be expanded due to intramolecular 
electrostatic repulsions, resulting in macromolecule stiffness. 
The strength of complexation depends on the charge density of the polymers. 
The charge density of weak polyelectrolytes is governed mainly by the pH, which is 
why solution pH plays a crucial role on the coacervation process 208-212. A pH value has 
been defined for synthetic polyelectrolytes and proteins at which soluble complexes 
are formed and that preceded the pH of visual phase separation 213-218. Weinbreck et 
al. proved that pH-induced structural transitions occurred for GA and whey protein 
219. Here structural transitions of GA/Ch complexes are described, at constant pH, by 
changing the Ch degree of deacetylation (charge density). Complexes prepared with 
chitosan DD75 at 0.03% detected by DLS appeared to be soluble, as there was no 
phase separation and the turbidity was low (up to RGA/Ch of 1.2). However, using Ch 
DD93, the turbidity increased already at low concentrations. There is an optimum 
concentration where complex coacervation is maximum 220. Previous studies 
demonstrated that at chitosan concentrations of 0.5–1%, GA/Ch complexes 
precipitate at pH 4.5, particularly at ratios of 4 and 5 158. Our studies were performed 
with chitosan concentrations of 0.03 and 0.15% at RGA/Ch ≤ 3. Although GA/Ch ratios 
were kept low, at which soluble complexes are expected,205 insoluble complexes 
evidenced by increased turbidity, were also observed.  
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5.2.1.2 Imaging gum Arabic-chitosan complexes 
GA/Ch75 complexes prepared with 0.03% of chitosan and weight ratios of 0.6 
and 1.2 have a globular shape when adsorbed onto the polar mica substrate (Figure 
5.3). The AFM images and section analysis also indicate that, after deposition on 
substrates, the complexes collapse into a core structure surrounded by a rough layer 
(Figure 5.3A). A profile analysis of an agglomerate observed at ratio of 1.2 (GA/Ch) 
(dashed line in Figure 5.3B) evidences diameters of 200-250 nm. 
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Phase analysis shows more contrast than the topographic one as well as more 
sensitivity to material surface properties such as stiffness and viscoelasticity. GA/Ch75 
complexes (weight ratio of 0.6 and 0.03% Ch) are agglomerates of homogeneous 
material as they show the same bright colour (Figure 5.4). 
 GA/Ch 0.6 A  GA/Ch 1.2 B 
 
 
 
Figure 5.3 AFM height images of GA/Ch75 complexes at chitosan 
concentration of 0.03%: (A) RGA/Ch = 0.6 and (B) RGA/Ch = 1.2 
(scale bar = 200 nm). The profile analysis of the complexes is 
shown below evidencing the complex core structure 
surrounded by a rough layer at RGA/Ch of 0.6 and one  particle 
aggregate of 220 nm at RGA/Ch = 1.2.  
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GA/Ch93 complexes prepared with 0.03% of Ch form more uniform structures 
with spherical shape (Figure 5.5A). The average diameters, based on 20−30 direct 
measurements from AFM micrographs, are 240 ± 60 nm for RGA/Ch 1.2, which are in 
agreement with DLS measurements. Phase images show particle aggregates and soft 
material surrounding the particles (dark areas are softer then bright areas) (Figure 
5.5B). The differences between particle core and surroundings are attributed to 
viscoelastic properties of the material. The core is composed of hydrophobic 
aggregates (neutralized segments of GA and Ch) which are harder than free charged 
segments of Ch or polar non charged segments of GA. 
 
 
GA/Ch 0.6 
 
   60.0º 
 
 
Figure 5.4 AFM phase image of GA/Ch75 complex at RGA/Ch = 0.6 and Ch 
final concentration of 0.03%.  
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At higher biopolymer concentrations (CCh = 0.15%) the structure of the 
complexes is similar to that observed for 0.03% chitosan (Figure 5.6). A layer 
embedding the complexes is visible (Figure 5.6B).  
 GA/Ch 1.2 A 
 100 nm 
 
 
 B 
                    
Figure 5.5 Structure of GA/Ch93 complex at weight ratio of 1.2 and 
chitosan final concentration of 0.03%, viewed by AFM (scale 
bar = 500 nm).  
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Ch is positively charged and has a relatively extended conformation in solution, 
resulting that its charges are accessible 158, 221. GA, in contrast, is negatively charged 
(with low charge density) and has a globular structure 205, 222. Arising from 
electrostatic interaction, the two weak oppositely charged polyelectrolytes form a 
complex, thereby releasing counterions and water molecules, contributing to an 
entropy gain in the system 158, 223. GA forms, with Ch DD75, complexes with a 
relatively globular shape, but less uniform than the ones obtained with Ch DD93, 
which are spherical particles. GA/Ch75 complexes appear also more polydispersed 
and flattener (their diameter: height ratios typically exceeded 10:1 at CCh = 0.03%), 
when compared with the particles formed by GA/Ch93. Ch molecules DD93 have 
more positive charges and efficiently neutralized the negatively charges of GA. The 
lower charge density of Ch DD75 is most likely the cause for inefficient assembly of 
the macromolecules. The formation of irregular aggregates by GA and Ch DD75 is 
attributed to the presence of non-charged polar monomers in chitosan molecule. This 
hypothesis is based on the work of Wolfert et al. with copolymers of cationic and 
 
200 nm 
200 nm 
B 
100 nm C 
A 
 
Figure 5.6 AFM height images of GA/Ch75 (a) and GA/Ch93 (c) complexes, 
at weight ratios of 0.6 and Chitosan final concentration of  
0.15%. The profile analysis of GA/Ch75, shown in (b), evidences 
the presence of a rough embedding layer  
.
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uncharged monomers, which have lost their ability to condense deoxyribonucleic acid 
(DNA) 224. The copolymers could not induce hydrophobic self-assembly of 
polymer/DNA complexes even at charge neutrality. Also Sanchez et al. found vesicular 
structure for GA and lactoglobulin due to insufficiently neutralization of the 
macromolecular complexes 225.  
It is well known that the solubility of polyelectrolyte complexes depends 
strongly on the molar mixing ratio of the macromolecules and their relative molecular 
weights 226-229. Polyions with weak ionic groups that have significantly different 
molecular weights and/or are mixed in non-stoichiometric ratios form water-soluble 
micelle-like aggregates 228. Such complexes adopt a structure similar to the ladder 
model, consisting of hydrophilic single-stranded and hydrophobic double-stranded 
segments, where complex formation takes place on a molecular level via 
conformational adaptation (zip mechanism) 229. The formation of soluble GA/Ch 
complexes might follow a similar mechanism, due to large non-charged segments of 
GA (only approximately 23% of GA residues are charged). The driving force of complex 
formation is the release of counterions, but once the polyelectrolytes are in close 
contact, the distance between the charges also influences the complex structure. 
GA/Ch75 form, at low concentrations (CCh = 0.03%) and up to 1.2 ratio, soluble 
complexes (optical density low) with globular structure, whereas GA/Ch93 form 
spherical particles (insoluble complexes). The complexes appear to have a core-shell 
micellar structure, composed of hydrophobic core (charge neutralized segments) 
stabilized by non-neutralized Ch segments and non-charged segments of GA. The 
distance between the charges on the Ch molecule seems to have a higher influence 
on the structure of the complexes than the charge ratio itself, as observed in the case 
of cationic polymers and DNA complexes 224. In addition to the degree of 
deacetylation of Ch, the formation of nanoparticles was dependent on the 
concentrations of the polymers, as observed for other cases such as for Ch-dextran 
system 230. For both systems, small particles were formed only by using dilute 
polysaccharide solutions (final total concentration less than 0.07%). Similar results are 
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described for the system poly-gamma-glutamic acid and Ch. At low concentration of 
biopolymers, more stable nanocomplexes were formed, and the formation of smaller 
individual nanoparticles was favoured 231.  
 
The objective of this characterization was to develop and optimize a system 
that could be used to deliver an anticancer drug. GA/Ch93 form soluble complexes 
with spherical structure of about 240 nm at weight ratios up to 1.2, if the 
concentrations are kept low (total biopolymer concentration up to 0.06%). Thus, 
these parameters were used to prepared BTZ and AuNPs-loaded polysaccharide NPs. 
 
5.2.2 Particle size distribution, surface charge and 
morphology of BTZ loaded Ch-GA NPs and BTZ+PEGAuNPs loaded 
Ch-GA NPs 
The Ch-GA based nanoparticles alone and loaded with PEGAuNPs and BTZ were 
prepared through a coacervation process. The initial concentration of chitosan was 
0.04% (w/v) and a GA/Ch weight ratio of 1.2 was used.  Figure 5.7A and Figure 5.7B 
confirmed the presence of PEGAuNPs inside the complexes without and with BTZ, 
respectively.  
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The Ch-GA-BTZ+PEGAuNPs show two typical absorption bands centered at 
528.5 and 268.5 nm from PEGAuNPs and BTZ, respectively (data not shown). These 
nanosystems were stable for several weeks when stored at 4ºC in the dark. DLS 
measurements were in agreement with the TEM analysis, and are shown in Table 5.2.  
 
 
Table 5.2 Hydrodynamic diameter, polydispersity index (PdI) and zeta 
potential of nanoparticle systems with  initial Ch concentrations 
of 0.04% (w/v) and a RGA/Ch = 1.2. 
Sample CBTZ 
(nM) 
CPEGAuNPs 
(nM) 
Diameter 
(nm) 
PdI ZP 
(mV) 
pH 
Ch-GA - - 315 ± 5 0.3 39 ± 1 4.8 
PEGAuNPs  
(stock solution) 
- 18.9 39 ± 1 0.6 -39 ± 3 5.3 
Ch-GA-PEGAuNPs - 2 428 ± 18 0.3 23 ± 3 4.7 
Ch-GA-BTZ 200 - 341 ± 26 0.1 30 ± 3 4.8 
Ch-GA-PEGAuNPs-BTZ 200 2 327 ± 73 0.2 33 ± 2 4.6 
 
 
 
Figure 5.7 Transmission electron microscope images of (A) Ch -GA-
PEGAuNPs, (B) Ch-GA-BTZ+PEGAuNPs. Scale bar represent 200 
nm. 
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The average hydrodynamic diameter of Ch-GA NPs ranged from 315 nm to 327 
nm (loaded with PEGAuNPs) and the polydispersity index (PdI) was 0.3. This diameter 
change occurs due to the presence of spherical PEGAuNPs with small diameters (39 
nm). In BTZ loaded Ch-GA-PEGAuNPs, no significant change in the nanoparticle 
diameter was observed. 
The average zeta potential was positive for the different formulations, which is 
attributed to the residual amine groups of Ch that neutralize the negative charges of 
GA and PEGAuNPs. Also, the strong positive charges on the surface of nanoparticles 
prevent the aggregation (Table 5.2) 130, 134, 232 . 
5.2.3 In vitro release studies 
The release profiles of BTZ from Ch-GA NPs and Ch-GA-PEGAuNPs were studied 
in vitro using a dialysis membrane in ultrapure water and in PBS 0.01 M at 37 ºC. The 
results are shown in Figure 5.8.  
 
 
  
The drug release from Ch-GA-BTZ+PEGAuNPs and Ch-GA-BTZ NPs is pH 
dependent as it can be seen from the profiles in ultrapure water (pH 5.8) and in PBS 
 
Figure 5.8 Release profiles of Ch -GA-BTZ+PEGAuNPs ( ), Ch-GA-BTZ NPs (■) 
and BTZ alone (▲) in DI water (A) and PBS 0.01 M (B). Cma x  
corresponds to the total amount of BTZ added.   
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0.01 M (pH 7.0). In DI water, the amount of BTZ release from Ch-GA-BTZ+PEGAuNPs 
and Ch-GA-BTZ NPs is lower than the amount detected in the sample with only free 
BTZ (Figure 5.8A). After 5 h 40% of the total BTZ was released, which might be 
attributed to diffusion of BTZ from the nanosystems Ch-GA-BTZ NPs and Ch-GA-
BTZ+PEGAuNPs. Also, after 13 h, 51% was released from Ch-GA-BTZ+PEGAuNPs and 
Ch-GA-BTZ NPs, and 82% of BTZ alone was released. The release of BTZ in PBS is very 
different as depicted by the profiles of Figure 5.9B. In PBS, a delay in BTZ released 
from Ch-GA-BTZ+PEGAuNPs is observed in the first 5 h due to the presence of 
PEGAuNPs, comparing to the Ch-GA-BTZ NPs. For these systems, the BTZ release after 
10 h was 85%. Also, PBS provides an effect on BTZ adsorption of Ch-GA-BTZ NPs and 
Ch-GA-BTZ+PEGAuNPs systems, slowing down the BTZ release for the last 
nanoparticles. 
5.2.4 Cellular imaging studies 
The cellular uptake of Ch-GA-BTZ+PEGAuNPs with BTZ concentration of 100 nM 
in pancreatic cells (S2-013) and immortalized human pancreatic duct epithelial cells 
(hTERT-HPNE) was investigated by confocal microscopy. From our observations we 
can conclude that PEGAuNPs were internalized and distributed throughout S2-013 
and hTERT-HPNE cells after 48 h incubation, as illustrated in Figure 5.9c and Figure 
5.9d. It was observed that the accumulation of the nanoparticles into the cytoplasm 
effectively improve the cytotoxicity in both cell lines. 
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5.2.5 Cytotoxic studies 
The in vitro cytotoxicity studies of the effects of Ch-GA-PEGAuNPs, Ch-GA NPs, 
BTZ alone, Ch-GA-BTZ+PEGAuNPs and Ch-GA-BTZ NPs were performed with S2-013 
and hTERT-HPNE. The cells were exposed to a range of experimental concentration of 
BTZ loaded nanoparticles and blank nanoparticles for 48 h at 37ºC. Their effect was 
evaluated by SRB and PB methods. Ch-GA-PEGAuNPs and Ch-GA NPs with Ch 
concentration up to 3.3x10-3 mg/mL and RGA/Ch of 1.2 do not show any cytotoxicity on 
both cell lines (Figure 5.10), showing good biocompatibility.  
 
Figure 5.9 Transmission images of the S2-013 (a, c) and hTERT-HPNE (b, d) 
cells after 48 h incubation. The cells were incubated with Ch -
GA-BTZ+PEGAuNPs with BTZ concentration of 100 nM; (a,b) 
the control untreated cells. Scale bar is 10 μm .  
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The inhibitory effect of BTZ on the proliferation of S2-013 and hTERT-HPNE was 
evaluated with the drug incorporated in the NPs, Ch-GA-BTZ+PEGAuNPs and Ch-GA-
BTZ NPs. The effect of BTZ at concentrations from 0.1 to 100.0 nM was tested in these 
two systems with concentrations of Ch in the range 1.1x10-7 to 3.3x10-3 mg/mL and 
RGA/Ch of 1.2 (Figure 5.11).  
 
 
Figure 5.10 Cytotoxicity induced by  Ch-GA-PEGAuNPs (●)  and Ch-GA NPs 
( ) at RG A /C h  = 1.2 on S2-013 (A) and hTERT-HPNE (B) cells, by 
the SRB assay.  
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As presented in Figure 5.11A and Figure 5.11C, BTZ loaded Ch-GA NPs and BTZ 
loaded Ch-GA-PEGAuNPs decrease the growth rate of the S2-013 cells, when 
compared with BTZ alone, especially to 1.0 and to 10.0 nM of BTZ concentration. A 
possible reason for the efficacy increase of cytotoxicity of BTZ is the efficient delivery 
by the nanoparticles. Ch-GA system might augment protection of BTZ. Also for 10.0 
nM BTZ loaded in Ch-GA NPs and loaded in Ch-GA-PEGAuNPs reduced the cell growth 
to about 13% compared with 58% to BTZ alone. This suggests a good efficiency of the 
Ch-GA nanosystem through the EPR effect  200. Moreover, at this concentration range 
Ch-GA-BTZ+PEGAuNPs does not show toxicity to hTERT-HPNEs (Figure 5.11D).  
The inhibiting cell growth effect of BTZ loaded Ch-GA NPs and Ch-GA-PEGAuNPs 
were achieved by following SRB assay. In fact, as showed in Figure 5.12 and Table 5.3, 
 
 
Figure 5.11 Effect of the Ch-GA-BTZ+PEGAuNPs (●), Ch-GA-BTZ NPs (■) and 
BTZ alone (▲) on the cell growth of S2-013 (A, C) and hTERT-
HPNE (B, D) cells.  (A, B) PB assay and (C, D) SRB assay.  
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there is an increase of cell death with the increase of BTZ concentration, which is 
given by the analysis of the cell proliferation and cell death.  
 
 
 
 
 
In S2-013 cells, the GI50 concentration is lower in the case of Ch-GA-
BTZ+PEGAuNPs (0.47 nM) and Ch-GA-BTZ NPs (0.83 nM) when compared to BTZ alone 
(13.95 nM) (p < 0.05). Also, Ch-GA-BTZ+PEGAuNPs are more efficient in inducing cell 
death than BTZ alone for drug concentrations over 1.0 nM. BTZ alone is significantly (p 
< 0.05) more effective at decreasing cell survival and has more inhibitory effect on cell 
Table 5.3 Effect of BTZ, Ch-GA-BTZ NPs and Ch-GA-BTZ+PEGAuNPs on the 
growth inhibition of the pancreatic cell  l ines S2 -013 and hTERT-
HPNE. 
 GI50 (nM) 
Sample S2-013 hTERT-HPNE 
BTZ 0.74 ± 0.35 1.49 ± 0.20 
Ch-GA-BTZ 0.21 ± 0.06 10.0 ± 0.00 
Ch-GA-PEGAuNPs-BTZ 0.60 ± 0.00 23.86 ± 22.40 
 
 
 
 
 
 
 
 
Figure 5.12 Effect of the Ch-GA-BTZ+PEGAuNPs (●), Ch-GA-BTZ NPs (■) and 
BTZ alone (▲) on the cell growth of S2-013 (A) and hTERT-HPNE 
(B) cells compared to the control, by the PB assay.  
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growth, as it presents the lowest GI50 value (Table 5.3). Moreover, Figure 5.12 show 
that BTZ loaded nanoparticles decrease significantly the S2-013 cell growth rate when 
compared to BTZ alone. Also, it is showed that in hTERT-HPNEs the same effect is not 
observed. In fact, hTERT-HPNE cell growth did not change with BTZ loaded 
nanoparticles in the concentration range of 0.1 and 100.0 nM (Figure 5.12B). This 
could be explained by the effect of the carbohydrate matrix on the BTZ release in 
normal cells. 
5.3 Conclusions 
A novel chitosan-gum Arabic-gold nanoparticle system with positively charged 
was developed for the delivery of the proteasome inhibitor, bortezomib. BTZ was 
entrapped into the polysaccharides-gold nanoparticles’ system. Confocal images 
indicate that Ch-GA-BTZ+PEGAuNPs were internalized by the pancreatic cells through 
endocytic mechanism and are able to enhance permeation and retention of BTZ 
activity. There is a decreasing in the required drug concentration to induce cell 
proliferation. The in vitro cytotoxic study revealed that 10.0 nM BTZ loaded Ch-GA-
PEGAuNPs had a significant toxicity to human pancreatic cancer cells as compared to 
the drug alone. Also, at the same BTZ concentration, the nanosystem has no toxic 
effect to immortalized human pancreatic duct epithelial cells, suggesting that these 
nanoparticles can have good applicability to overcome limitations associated to low 
bioavailability, in situ delivery and, therefore, fewer side effects. 
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 6 Concluding Remarks 
 
This thesis reports the concept of enhancing the effect of anticancer drugs on 
cancer cells by pegylated gold nanoparticles. Our approach is based on the increase of 
the permeation and retention effect by the functionalized gold nanoparticles in 
prostate and pancreatic cancer cells, and opens the possibility to overcome multi-
drug resistance 
In cell cultures, our results show that gold nanoparticles intensify the 
anticancer response of the drug bortezomib, a proteasome inhibitor. The pegylated 
gold nanoparticles localized at the perinuclear regions enhance the toxicity of 
bortezomib in both types of cancer cells.  
 Our concept is based on the formation of endocytic vesicles with high electron 
density where the nanoparticles move at high speed, increasing the drug mass 
transfer rate across cell membranes and diffusion process in the cytoplasm to 
perinuclear region. The effect of this mechanism on the drug mass transfer rate 
across cell membranes and diffusion process can be further explored by the research 
teams working in the development of new anticancer drugs.  
The incorporation of bortezomib and pegylated gold nanoparticles into a 
positively charged chitosan-gum Arabic-gold matrix was also evaluated. The objective 
of this work was to protect the systemic bioavailability of BTZ and avoid that normal 
cells are exposed to the drug toxicity. The results demonstrated that the toxicity in 
normal cells decreases, suggesting the potential of these nanoparticles to protect the 
drug activity and reduce the side effects. 
The design of suitable nanocarriers for molecular transport can be fine-tuned to 
influence the enhanced permeation and retention effect. Since no chemical 
modification of the drug is needed, the present approach can be potentially applied 
to other anticancer drugs with potential efficacy in the angiogenesis process. The 
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benefits of this approach for future cancer drugs/therapies/diagnosis require further 
research to evaluate in vivo drug efficacy to understand the pharmacokinetics, 
pharmacodynamics and response of the immune system to the nanosystems.  
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